



CENTER FOR CLINICAL GUIDELINES | CANCER

# Radiotherapy Guidelines 2025

## Danish Head and Neck Cancer group

### Version 2.0

#### **APPROVAL**

##### **Content approval**

03.05.2025 (DAHANCA)

##### **Administrative approval**

DD. MM. YYYY (Center for Clinical  
Practice Guidelines | Cancer)

#### **REVISION**

Planned: 01.01.2026

#### **KEYWORDS**

Head and neck cancer, radiotherapy,  
quality assurance

## Content

1. Anbefalinger – Dansk (Quick guide).....	3
Target delineation (GTV).....	3
Normalt væv .....	5
Samlet behandlingsplan for vurdering og planlægning af re-irradiation .....	5
Stråledosisplanlægning.....	5
Kompleks dosisplanlægning.....	5
Behandling.....	5
Særlige overvejelser ved protonterapi.....	5
Behandlingsforlængelser .....	5
Strålebehandlings-kvalitetssikring .....	5
Lymfeknudemetastaser fra ukendt primærtumor (UP) .....	6
Recommendations English (Quick guide) .....	6
Target delineation (GTV).....	6
Definition of volumes beyond the GTV.....	7
Normal tissues.....	8
Cumulated treatment plan for evaluation and planning of re-irradiation.....	8
Radiotherapy dose planning.....	9
Radiotherapy quality assurance .....	9
2. Introduction.....	9
3. Scientific basis .....	1
Target delineation (GTV).....	1
Definition of volumes beyond the GTV.....	6
Normal tissues.....	11
Cumulated treatment plan for evaluation and planning of re-irradiation.....	17
Radiotherapy dose planning.....	17
Complex dose planning .....	20
Special considerations for proton therapy .....	24
Treatment prolongations .....	25
Version 2.0	

Radiotherapy quality assurance .....	25
Guidelines for elective lymph node irradiation.....	28
Oral Cavity.....	28
Nasopharynx.....	30
Oropharynx .....	31
Hypopharynx.....	33
Supraglottic larynx .....	34
Glottic larynx .....	34
Subglottic larynx.....	35
Sinonasal tumours.....	36
Salivary gland.....	38
Lymph node metastasis from unknown primary tumour (UP).....	40
4. References.....	41
5. Method.....	1
6. Monitoring.....	1
7. Appendices.....	2
8. About this clinical guideline.....	9

# 1. Anbefalinger – Dansk (Quick guide)

## Target delineation (GTV)

1. Alle trin i immobilisering, scanning, billedrekonstruktion, overførsel og co-registrering skal kvalitetssikres (D)
2. Alle scanninger anvendt til target-delineation ved kurativ strålebehandling må højst være 3 uger gamle (D)
3. Den ansvarlige onkolog bør deltage i alle dele af target-definitionen i komplekse tilfælde (D)

### *Planning CT*

4. En planlægnings-CT af optimal kvalitet med brug af metalartefakt-reduktion skal optages med en maksimal snittykkelse på 2 mm (D)

### *Anbefalede MRI-sekvenser til delineation*

5. MRI-sekvenser til target-delineation bør være T1 med og uden kontrast + T2 med og uden fedtsuppression (STIR/Dixon) (D)

### *PET-CT*

6. Procedurer relateret til PET/CT skal følge EANM-retningslinjerne fra 2015 (D)

### *Farynx og mundhule*

7. PET-CT og MRI bør anvendes til target-delineation af kræft i farynx og mundhule. Områder med særlig opmærksomhed er perineural invasion, knogle- og kraniebundsinvansion

### *Larynx*

8. PET-CT og MRI bør anvendes til target-delineation af kræft i larynx (D)
9. Ved tumorer, der ikke er synlige på de diagnostiske scanninger (f.eks. T1N0 larynxcancer), er PET og MRI ikke indiceret (D)
10. Undersøgelse i generel anæstesi, tegninger eller fotos bør anvendes til delineation af overfladisk udbredte tumorer (D)

11. PET-CT og MRI bør anvendes til target-delineation af sinonasale og spytkirteltumorer (D)
12. Valget af billedmodalitet følger primærtumoren. Ved ukendt primærtumor følges enten retningslinjer for postoperativ strålebehandling (kun MRI) eller kurativ strålebehandling (PET-CT + MRI) (D)
13. Indikation for postoperativ strålebehandling besluttet på multidisciplinær teamkonference (D)
14. Alle tilfælde af T3/T4, ENE, højrisiko-histologi og ikke-radikal operation skal diskuteres på multidisciplinær teamkonference (D)

### **Target-definition**

15. Også ved postoperativ strålebehandling skal al tilgængelig information anvendes til target-delineation (D)
16. Optimal navngivning og markering af operationspræparatet er essentiel for optimal delineation af f.eks. extranodal extension (ENE) eller R1-resektioner (D)
17. Komplekse targetområder bør defineres i samarbejde med den opererende kirurg (D)

### **Billeddiagnostik**

18. MRI bør anvendes til target-delineation ved postoperativ strålebehandling, undtagen hvis der ikke var synlig præoperativ tumor og ingen rekonstruktion, f.eks. T1 glottis larynx (D)
19. Der er ingen indikation for PET-CT ved umiddelbar postoperativ strålebehandling, medmindre makroskopisk tumor mistænkes, eller halsen skal vurderes (D)

### **Definition af volumina ud over GTV**

20. Nomenklaturen fra ICRU skal anvendes, og definitioner af nodale niveauer skal følge internationale konsensusretningslinjer (D)
21. CTV1 inkluderer GTV med 5 mm geometrisk margin, tilpasset naturlige grænser for tumorspredning (D)
22. CTV2 inkluderer GTV med 10 mm geometrisk margin, tilpasset naturlige grænser for tumorspredning (D)

23. CTV3 inkluderer CTV2 og elektive områder (D)

### ***GTV og CTV ved postoperativ strålebehandling***

24. CTV1 inkluderer den præoperative ikke-radikalt opererede tumor (R1 eller R2) med en isotropisk margin på 5 mm, tilpasset anatomiske barrierer for tumorspredning (D)

25. CTV2 inkluderer præoperativ GTV med 10 mm margin, tilpasset anatomiske barrierer for tumorspredning (D)

26. CTV3 inkluderer CTV2, operationsområdet og elektive volumina (D)

### ***GTV og CTV ved strålebehandling efter induktionskemoterapi (nasopharynx, sinonasal cancer)***

27. Efter induktionskemoterapi kan det aktuelle target delineeres. Det bør overvejes at inkludere præ-kemoterapi involverede volumina, især vedrørende knogle, kraniebund og involverede bihuler (B)

## Normalt væv

28. Nomenklatur (D), dosis-volumen begrænsninger (C) og definition af volumina (D) skal følge retningslinjerne i Tabel 1 og Appendix 1.

## Stråledosisplanlægning

29. Dosisplanlægning bør tilstræbe at overholde tolerancegrænserne for target-dækning og normalvævs-beskyttelse som beskrevet i Tabel 2 (D)

## Kompleks dosisplanlægning

30. Dosisplanlægning bør stræbe efter at opnå tolerancer for target-dækning og normalvævs-beskyttelse som nævnt i Tabel 2 (D)

## Recommendations English (Quick guide)

### Target delineation (GTV)

1. All steps in immobilisation, scanning, image reconstruction, image transfer and co-registration should be quality assured (D)
2. All scans used for target delineation in radical radiotherapy should be less than 3 weeks old (D)
3. The responsible oncologist should take part in all parts of the target definition in complex cases (D)

### *Planning CT*

4. A planning CT scan of optimal quality with the use of metal artefact reduction should be acquired with a maximal slice thickness of 2 mm (D)

### *Recommended MRI sequences for delineation*

5. MRI sequences for target delineation should be T1 with and without contrast + T2 with and without fat suppression (STIR/ Dixon) (D)

### *PET-CT*

6. The procedures related to PET/CT should follow EANM guidelines from 2015 (D)

### *Pharynx and oral cavity*

7. PET-CT and MRI should be used for target delineation of cancers in the pharynx and oral cavity. Areas of special attention are perineural invasion, bone and skull base invasion (D)

### *Larynx*

8. PET-CT and MRI should be used for target delineation of cancers in the larynx (D)
9. In case of tumours not visible on the diagnostic scans (e.g. T1N0 larynx cancer), PET and MRI are not indicated (D)

10. Examination in general anaesthesia, drawings or photos should be used for the delineation of superficially spreading tumours (D)
11. PET-CT and MRI should be used for target delineation of sinonasal and salivary gland cancers (D)
12. The choice of imaging modality follows the primary tumour. In case of unknown primary, it follows either the guidelines for post-operative radiotherapy (MRI only) or radical radiotherapy (PET-CT + MRI) (D)
13. The indication for postoperative radiotherapy is decided at a multidisciplinary team conference (D)
14. All cases of T3/T4, ENE, high risk histology and non-radical surgery, must be discussed at the multidisciplinary team conference (D)

### ***Target definition***

15. Also for postoperative radiotherapy, all available information must be used for target delineation (D)
16. Optimal naming and marking of the surgical specimen are essential for optimal delineation of e.g. extranodal extension (ENE) or R1 resections (D)
17. Complicated targets should be defined with the operating surgeon (D)

### ***Imaging***

18. MRI should be used for target delineation in post-operative radiotherapy, except when there was no visible pre-operative target and no reconstruction, e.g. T1 glottic larynx (D)
19. There is no indication for PET-CT in immediate post-operative radiotherapy, unless macroscopic tumour is suspected, or the neck needs evaluation (D)

## **Definition of volumes beyond the GTV**

20. The nomenclature of volumes by the ICRU should be applied, and the definitions of nodal levels according to international consensus guidelines should be followed (D)

21. CTV1 includes GTV with 5 mm geometric margin, modified for natural borders for tumour spread (D)
22. CTV2 includes GTV with 10 mm geometric margin, modified for natural borders for tumour spread (D)
23. CTV3 includes CTV2 and elective areas (D)

#### ***GTV and CTV in postoperative radiotherapy***

24. CTV1 includes the pre-operative non-radical operated tumour (R1 or R2) with an isotropic margin of 5 mm modified for barriers for tumour spread (D)
25. CTV2 includes preoperative GTV with 10 mm margin modified for barriers for tumour spread (D)
26. CTV3 includes CTV2, surgical bed and elective volumes (D)

#### ***GTV and CTV in radiotherapy after induction chemotherapy (nasopharynx, sinonasal cancer)***

27. After induction chemotherapy, the actual target may be delineated. It should be considered to include, pre-chemotherapy involved volumes especially concerning bone, skull base and involved sinuses (B)

### Normal tissues

28. The nomenclature (D), dose-volume constraints (C), and definition of volumes (D) should follow the guidelines of Table 1 and Appendix 1.

### Cumulated treatment plan for evaluation and planning of re-irradiation

1. A cumulated treatment plan, even corrected for recovery and fractionation, may be beneficial for the planning of re-treatment, but physical and biological uncertainties should be considered (D)

## Radiotherapy dose planning

**29. Dose planning should attempt to comply with the tolerance levels for target-coverage and normal tissue sparing described in Table 2 (D)**

## Radiotherapy quality assurance

**30. Dose planning should strive to achieve the tolerances for target-coverage and normal tissue sparing mentioned in table 2 (D)**

## 2. Introduction

Head and neck cancer is a heterogeneous group of cancers located between the base of skull and the clavicles. The anatomical region is characterized by an abundance of critical normal structures, important for senses, appearance, breathing, communication, and eating. The population of patients with head and neck cancer varies with a large proportion of patients having a smoking-induced cancer, and thus, a high risk of co-morbidity and socio-economic problems. The number of patients with head and neck cancer is slightly increasing due to an increase in the number of HPV-induced oropharyngeal cancers. In 2022, 852 patients received radiotherapy for head and neck cancer with curative intent (annual report 2022 of the Danish Head and Neck Cancer Group, DAHANCA). Unfortunately, radiotherapy often leads to severe acute and late side effects. Both side effects and the chance of cure are very dependent on the quality of radiotherapy. DAHANCA has a long standing tradition for conducting clinical trials as well as establishing national guidelines for radiotherapy for head and neck cancer to improve outcome. DAHANCA guidelines and treatment recommendations have been applied worldwide.

The evidence for the recommendations is scarce, and based on indirect conclusions from retrospective studies modelling the risk of side effects and likelihood of loco-regional tumour control, as well as technical studies on the inaccuracies of radiation equipment and uncertainties in treatment setup. Nevertheless, the recommendations for adhering to the guidelines is strong as the possibility to evaluate the treatment quality on a national level depends on the consistency of the treatment. Overall, the guideline is a product of discussions within in the DAHANCA radiotherapy quality assurance group and endorsed by DAHANCA (Level 5 evidence). When nothing else is mentioned, this forms the evidence of the guidelines, and specific literature review is not included in the chapters which may be characterized as a “cookbook”.

Nevertheless, DAHANCA is very concerned about adherence to the guidelines and has evaluated the clinical consequences. DAHANCA has thoroughly analysed and reported on these issues(1-3).

As mentioned, several international groups have evaluated previous editions of the present guidelines, and thereby produced new recommendations (4, 5). These guidelines have, in turn, to some extent been incorporated into the present edition.

High quality radiotherapy is to a large extent driven by development in equipment and software technology and is as such a very dynamic field. The need for research, quality assurance, and evaluation of new techniques is therefore a continuous process that continuously must be implemented via endorsed national clinical guidelines to ensure equal and high levels of treatment quality.

### Objective

The overall objective of this guideline is to support high quality cancer care across the Danish healthcare system.

The specific objective of the present guidelines is to secure a high and consistent quality of radiotherapy for patients with head and neck cancer. To increase the quality of care, both within and outside of clinical protocols, we strive for a high degree of consistency and adherence to guidelines.

### Patient population

Radiotherapy for all patients with head and neck cancer can be planned according to the principles of the guidelines.

### Target users

This guideline is developed to support clinical decision-making and quality improvement. Thus, the target users are healthcare professionals working in Danish cancer care. The guidelines are applicable to all treatments in the head and neck area and should serve as a guideline for radiotherapy at all Danish centres treating head and neck cancer patients. They are applicable for the whole process of radiotherapy from scanning, target delineation, dose planning, and evaluation and quality assurance and should therefore guide both physicians and physicists involved in radiotherapy for head and neck cancer.

### 3. Scientific basis

#### Target delineation (GTV)

To cure a patient, one must ensure that all clonogenic cells receive a tumoricidal dose. I.e. that the target is covered by a relevant dose. Tumour deposits can be seen far from the bulk of disease, i.e. in lymph nodes or via perineural spread. These deposits will not be covered by the clinical target volumes irrespectively of the GTV to CTV margin size. Utmost care must therefore be put into the delineation of the GTV, and all available information must be used. According to the ICRU 83, the GTV is the gross demonstrable extent and location of the tumour. All examinations and imaging modalities which provide information on the extent and location of the tumour should be used, e.g. clinical examination, anatomic imaging and functional imaging.

- 2. All steps in immobilisation, scanning, image reconstruction, image transfer and co-registration should be quality assured (D)**
- 3. All scans used for target delineation in radical radiotherapy should be less than 3 weeks old (D)**
- 4. The responsible oncologist should take part in all parts of the target definition in complex cases (D)**

The extent of disease outside what is defined as GTV with the available information can be evaluated by four distinctly different methods, that supplement each other: 1) Pathology examination of surgical specimens, e.g.(6-9). 2) evaluating the macroscopic tumour extent on surgical specimens with respect to different imaging modalities e.g. (10-13)3) Evaluating the recurrence pattern with respect to target definition and dosimetry(1, 14-18), and finally 4) Evaluating tumour spread on imaging and from that inferring frequent routes of progression (19, 20) . With the available evidence, it is not obvious that geographical miss is the dominant problem on a population basis. This is important to keep in mind when margins are discussed. Larger treatment volumes may prohibit treatment intensification or reduce compliance due to side effects(1, 21). Nevertheless, optimal GTV definition remains critical for optimal radiotherapy of the individual patient.

In radiotherapy, the planning CT is the reference imaging, as this is the basis for correct dose planning and treatment setup. Information from other scans must therefore be evaluated with respect to anatomical and geographical precision. That is, co-registration must be evaluated regardless of whether it is performed rigidly or deformable.

Imaging acquired in non-treatment position, e.g. diagnostic MRI or PET-CT scans, can be used for target delineation. The scans should not be more than 3 weeks old (consensus), otherwise they must be repeated or used with extreme caution.

Ideally, the same oncologist should be involved in the entire patient trajectory, from staging at the MDT to patient information and discussion of expected and accepted side effects to target definition. This is especially

important in case of advanced disease or potentially serious side effects, e.g. double-sided blindness or brainstem injury.

### ***Planning CT***

#### **5. A planning CT scan of optimal quality with the use of metal artefact reduction should be acquired with a maximal slice thickness of 2 mm (D)**

The optimal scan quality of the CT is important and metal artefact reduction should be used(22). Slice thickness should not be larger than 2 mm. Intra-venous contrast should be used for nodal evaluation, if a MRI in treatment position is not available. Field of view settings and pixel size should be evaluated as these can potentially change margins. On board imaging (CBCT, virtual CT) may be used for replanning in photon radiotherapy, if appropriately validated and continuously quality assured.

### ***Recommended MRI sequences for delineation***

#### **6. MRI sequences for target delineation should be T1 with and without contrast + T2 with and without fat suppression (STIR/ Dixon) (D)**

The recommended MRI sequences should be optimized to the local hardware such as scanner and coils. Priorities should be geometric stability, image quality, patient convenience and scanning in treatment position i.e. in immobilisation as well as resources. If available, 3D scans should be considered for geometric stability, but it will often be necessary to add axial scans for optimal image quality. Sequences optimized for image quality only, can lead to serious geometric distortions(23). The recommended sequences are T1 with and without contrast + T2 with and without fat suppression (STIR/ Dixon). Adding fat suppression sequences to T1 with contrast is recommended in cases of suspected intracranial or intraorbital spread. Diffusion weighted imaging including ADC maps may be added. The order of sequences should be prioritized so that the most important sequences are done first in case the patient tolerates the scanning poorly (e.g:T1, T1+contrast, T2, DWI).

### ***PET-CT***

#### **7. The procedures related to PET/CT should follow EANM guidelines from 2015 (D)**

Whole body PET-CT scans can be used to detect distant metastasis or other primaries. In case the patient has been evaluated with 3D imaging below the clavicles, the PET-CT scan area for treatment planning does not need to be as large. Metal artefact reduction algorithms should be used, especially if the CT is used as the planning CT and not only for attenuation correction. A flat table couch and an immobilisation mask should ideally be used (24).

A nuclear medicine specialist, a radiologist and an oncologist should participate in the target delineation process, ideally at a multidisciplinary team conference with the purpose of target evaluation.

Nuclear medicine specialists and the radiologist (25-27) create a written description of the target, and this is stored together with the images in RIS/PACS archiving system.

### ***Pharynx and oral cavity***

- 8. PET-CT and MRI should be used for target delineation of cancers in the pharynx and oral cavity. Areas of special attention are perineural invasion, bone and skull base invasion (D)**

### ***Larynx***

- 9. PET-CT and MRI should be used for target delineation of cancers in the larynx (D)**
- 10. In case of tumours not visible on the diagnostic scans (e.g. T1N0 larynx cancer), PET and MRI are not indicated (D)**
- 11. Examination in general anaesthesia, drawings or photos should be used for the delineation of superficially spreading tumours (D)**

Areas of special attention are cartilage invasion and superficially spreading tumours.

### ***Cancer of nasal cavity, paranasal sinuses and the salivary glands***

- 12. PET-CT and MRI should be used for target delineation of sinonasal and salivary gland cancers (D)**

Areas of special attention are perineural invasion, bone, orbital and skull base invasion

### ***Nodal metastases***

- 13. The choice of imaging modality follows the primary tumour. In case of unknown primary, it follows either the guidelines for post-operative radiotherapy (MRI only) or radical radiotherapy (PET-CT + MRI) (D)**

The normal anatomical nodal characteristics should be considered: small size, kidney or bean shape, presence of hilus, homogenous cortex and hilar vascularity. Some of these characteristic are superiorly assessed with ultrasound, which should be considered. Deviations from these characteristics should be considered an indication for malignancy.

The malignancy criterion concerning size is measured in the shortest axis(28). The sensitivity, using this criterion alone is not high, and the morphological criteria should be weighted as well(29):

- Neck nodes in general: 10 mm
- Angular nodes (upper jugulo-carotid): 11 mm (30)
- Retropharyngeal nodes: 6 mm.
- Using functional imaging, other malignancy criteria might be used.

### ***Post-operative radiotherapy***

**14. The indication for postoperative radiotherapy is decided at a multidisciplinary team conference (D)**

**15. All cases of T3/T4, ENE, high risk histology and non-radical surgery, must be discussed at the multidisciplinary team conference (D)**

### ***Tasks to be clarified at the MDT conference***

The indication for post-operative radiotherapy should be discussed at the multidisciplinary team (MDT) conference between the operating surgeon and an oncologist as soon as the final pathology report becomes available. Hereafter, the conclusion is presented to and discussed with the patient. Ideally, all post-operative cases should be discussed at the MDT with respect to the indication of postoperative radiotherapy. As a minimum, all cases of T3/T4, ENE, high risk histology and non-radical surgery must be discussed between an oncologist and a surgeon. Lack of information in the pathology report and e.g. ambiguous nomenclature of specimens and large specimens with several nodal levels are other issues that must be clarified at the MDT conference. The target should be described in the medical report from the MDT conference.

### ***Target definition***

**16. Also for postoperative radiotherapy, all available information must be used for target delineation (D)**

**17. Optimal naming and marking of the surgical specimen are essential for optimal delineation of e.g. extranodal extension (ENE) or R1 resections (D)**

**18. Complicated targets should be defined with the operating surgeon (D)**

Except in case of macroscopic non-radical surgery/ debulking surgery, there is no GTV in post-operative radiotherapy. Nevertheless, it is of advantage for accurate target delineation, that a pre-operative tumour volume (pre-operative GTV) can be defined(31). Furthermore, the surgical bed should be defined with optimal accuracy irrespective of any reconstruction. Any area of non-radical surgery should also be defined with optimal precision. With all these considerations in mind, it is strongly recommended that the operating surgeon takes part in the target delineation, as a minimum for complex cases. Post-operative oedema and altered anatomy are typical issues that need special attention. The oncologist participating in the MDT conference and defining the target should be the same.

*Other considerations for postoperative target delineation*

To ensure optimal workflow and quality of the target definition, the operating surgeon should take preoperative photographs or make a tumour drawing, and make a thorough description of tumour extension, evaluated with the patient in general anaesthesia. Optimally, areas of anticipated narrow margins or e.g. ENE should be marked with surgical clips. Clips can also be used to mark the entire surgical bed(32).

**Imaging**

**19. MRI should be used for target delineation in post-operative radiotherapy, except when there was no visible pre-operative target and no reconstruction, e.g. T1 glottic larynx (D)**

**20. There is no indication for PET-CT in immediate post-operative radiotherapy, unless macroscopic tumour is suspected, or the neck needs evaluation (D)**

MRI has superior soft-tissue contrast that can be utilized to delineate the surgical bed. Furthermore, MRI for target delineation allows for comparison with pre-operative MRIs.

**Literature and evidence review**

The evidence is sparse and the recommendations are based on consensus or other guidelines

**Patient values and preferences**

Not relevant.

**Rationale**

Optimal delineation of the target is essential for high quality radiotherapy. All errors in this part of planning will result in systematic errors and therefore inferior-quality radiotherapy.

**Comments and considerations**

The guidelines for GTV delineation has (January 2020) been discussed among the DAHANACA Radiotherapy Quality Assurance group and imaging specialist from all centres. The present guidelines is the result of these discussions and will provide us with an opportunity to evaluate target delineation on a national level in the future.

## Definition of volumes beyond the GTV

### **21. The nomenclature of volumes by the ICRU should be applied, and the definitions of nodal levels according to international consensus guidelines should be followed (D)**

#### Literature and evidence review

Clinical target volumes (CTVs) and organs at risk (OARs) must be defined in the dose planning system for CT-based radiotherapy. The terminology for these volumes is defined by the ICRU. The relevant editions are ICRU 50 (1993), ICRU 62 (1999) and ICRU 83 (2010). The definitions in ICRU 83 and ICRU 62 are the same, but in the latter edition, the 'Remaining volume at risk' (RVR) – defined as CTV + OAR subtracted from the patient contour – is reported as an important volume for IMRT dose planning in order to avoid high dose areas outside the targets and to avoid unexpected late morbidity, including secondary cancer. The use of an internal margin in head and neck cancer radiotherapy is considered irrelevant according to ICRU 83 as a defined volume, but the internal margin should be included in the CTV.

#### **Definition of volumes according to ICRU**

1. *GTV* = gross tumour volume includes all verified tumour extensions from clinical examinations and all available scanning modalities. Other volumes such as "GTV\_preop", "GTV\_MR" or "GTV\_PET" may be defined.
2. *CTV* = clinical target volume includes GTV if present and subclinical tumour extension to the vicinity of the primary or lymph nodes. The CTV should also include a margin for internal changes and uncertainties e.g. shape, size and organ movement (rarely relevant for head and neck radiotherapy).
3. *PTV* = planning target volume is a geometrical volume defined to secure dose delivery to the CTV. The PTV includes uncertainties related to dose delivery including setup and mechanical uncertainties. The size of the PTV-margin is dependent on systematic and random uncertainties related to a specific treatment technique, local quality assurance and other specific local dependent factors. It should ideally be defined based on local measurements. The size of the PTV is generally defined by adding the square of the single independent uncertainties (ICRU 62). Note: PTV is not used for proton therapy. See the chapter on proton therapy.
4. *OAR* = organ at risk
5. *PRV* = planning risk volume = OAR + margin for internal movements and setup margin as described above. The PRV is mainly relevant for serially organized and small OAR volumes (lacrimal glands).
6. *RVR* = remaining volume at risk = CTV and OAR subtracted from the total patient volume
7. *TV* = treated volume = the volume receiving the prescribed dose.
8. *IV* = irradiated volume = volume receiving a dose relevant for normal tissue effects

#### **DAHANCA principles for target delineation**


### **22. CTV1 includes GTV with 5 mm geometric margin, modified for natural borders for tumour spread (D)**

**23. CTV2 includes GTV with 10 mm geometric margin, modified for natural borders for tumour spread (D)**

**24. CTV3 includes CTV2 and elective areas (D)**

DAHANCA uses the following volumes and definitions for radiotherapy: GTV is delineated based on examinations, imaging, pathology reports, drawings and other information. Elective regions are selected based on estimations of the risk of subclinical spread. There are two elective risk levels: high risk (CTV2) and low risk (CTV3). Low risk is defined as elective nodal regions with a risk for subclinical spread of at least 10%. The risk estimations, and thereby the recommended elective regions, are significantly different between the N0 and N+ neck.

When air is removed from the CTV (see below), it should also be removed from within the CTV, e.g. in the pharynx or paranasal sinuses, in order to improve optimization and reporting of dose.



**Figure 1.** Principles for target delineation and nomenclature

#### **GTV and CTV in radical radiotherapy**

**GTV:** Gross tumour in both T (GTV-T) and N (GTV-N) site evaluated by clinical examination and imaging.

**CTV1:** Includes the primary tumour (GTV-T) and involved nodes (GTV-N) with an isotropic margin of 5 mm, though larger if the tumour is poorly defined and smaller if the margin extends into air, uninvolved bone or other natural borders for tumour spread. That is, uninvolved bone is not included in the CTV1.

**CTV2:** Includes CTV1 and the surrounding volume outside CTV1 with the highest risk of subclinical tumour extension. It is defined as GTV with an isotropic margin of 10 mm. The margin may be less if it extends into air or surpasses natural borders such as bone.

Furthermore, a disease-specific high-risk anatomical region could be added. See the guidelines for the specific regions for details.

**CTV3:** Contains CTV2 and regional elective lymph nodes without margin. The CTV3 definition is highly dependent on nodal status. N0 and N+ are treated as recommended in Grégoire 2014(33), respectively. For N+ patients, the elective nodal regions are extended 2 cm cranially and caudally from any pathological lymph

nodes (GTV-N). The sternocleidomastoid muscle is included 2 cm above and below any pathological node GTV in case of suspected muscle involvement. In some regions, the Gregoire 2014 guidelines are ambiguous, and we have therefore produced a set of clarifying comments to the guidelines (Appendix 4).

***GTV and CTV in postoperative radiotherapy***

**25. CTV1 includes the pre-operative non-radical operated tumour (R1 or R2) with an isotropic margin of 5 mm modified for barriers for tumour spread (D)**

**26. CTV2 includes preoperative GTV with 10 mm margin modified for barriers for tumour spread (D)**


**27. CTV3 includes CTV2, surgical bed and elective volumes (D)**

***Preoperative-GTV:*** As defined from pre-operative clinical examination and imaging (See above).

In case of reconstruction with a flap: It is uncertain if the flap should be a part of the target. Recurrences within the flap are e(34)

***CTV1:*** Includes the pre-operative non-radically operated tumour (R1 or R2) with an isotropic margin of 5 mm, though larger if the tumour is poorly defined and smaller if the margin extends into air, uninvolved bone or other natural borders for tumour spread. That is, uninvolved bone is not included in the CTV1.

***CTV2:*** After R0 resection, CTV2 includes the preoperative GTV with an isotropic 10 mm margin. In case of non-radical resection, the CTV2 includes CTV1 with 5 mm margin. The margin may be larger in case of poorly defined tumour and less if it extends into air or surpasses natural borders such as bone. Furthermore, a disease specific high-risk anatomical region could be added. See the guidelines for the specific regions for details.



**Figure 2:** Examples of postoperative radiotherapy scenarios. I, II and III refer to elective nodal regions. Scenario A: Stage is the only indication for post-operative radiotherapy (R0) and thus, no CTV1 is present. Scenario B: Volumes with insufficient margins or ENE are included in CTV1. If there is only indication of post-operative radiotherapy in the T-site, but N0 disease, elective nodal regions are not treated. Scenario C: Well-defined pre-operative primary tumour GTV with R1 or R2 resection. Nodal areas with R0 resection and no ENE, but ill defined, e.g. several smaller positive nodes. In general: In case of well-defined pre-operative volumes, geometrical margins are applied. In case of ill-defined volumes or diffuse soft tissue invasion, entire nodal levels or anatomical regions (e.g. entire tongue) may be used as an anatomical margin.

**CTV3:** Contains CTV2 and the surgical bed of the primary tumour site outside preoperative GTV + 10 mm + regional elective lymph nodes without margin. The CTV3 definition is highly dependent on nodal status. See references above.

### **GTV and CTV in radiotherapy after induction chemotherapy (nasopharynx, sinonasal cancer)**

**28. After induction chemotherapy, the actual target may be delineated. It should be considered to include, pre-chemotherapy involved volumes especially concerning bone, skull base and involved sinuses (B)**

If patients are treated with induction chemotherapy, there is a large chance of response (95% had at least partial response) before radiotherapy and improved survival in nasopharynx cancer(35). Pre-induction-chemotherapy-GTV volume has been used for target delineation with unaltered margins(36). A randomized study comparing pre- versus post chemotherapy GTV irradiation showed no detrimental effect of reducing the target volume (37) and the long term results are gaining influence, as post-induction chemotherapy targets are often used(38). Bone or cartilage involved before induction chemotherapy is included in the high dose volume

(e.g. skull base or paranasal sinuses). In case of large tumours with good result of induction therapy, the CTV may be further modified to spare critical normal tissue. For involved nodes with visible soft tissue (ENE extension), the GTV-nodal is defined by the pre-ICT involved region.

CTV2 and CTV3 is identical to those of radical RT

### **PTV**

**PTV1, PTV2, PTV3:** Contains corresponding CTVs with uncertainties, including set-up margins (SM), that may vary with field localisation, patient immobilisation, and the use of image guided adaptive radiotherapy (IGRT). It is recommended that all departments gather data for their respective SM. PTV can be further divided into sub-volumes, e.g. close to surfaces or in case of overlaps with OAR and PRV.

In proton planning, the PTV margin is not used.

### **Example of workflow**

- 1) When present, GTV-T and GTV-N are delineated on basis of the above-mentioned recommendations
- 2) CTV1 is generated from GTV by adding an isotropic margin of 0-5 mm.
- 3) CTV2 is generated from GTV by adding an isotropic margin of 5-10 mm. CTV2 is modified for bone, air, skin, and specific anatomical consideration
- 4) CTV1 outside CTV2 is erased.
- 5) CTV3 is delineated according to atlases, available at [DAHANCA.oncology.dk](https://dahanca.oncology.dk).
- 6) Organs at risk are defined according to the treatment area and delineated according to atlases (defined in Appendix 1). The spinal cord must always be delineated, and the brain stem should be delineated at least in all cases with a defined CTV3.
- 7) Targets and organs at risk should be visualized in beams eye view to identify target and OAR irregularities and inconsistencies. The CTVs are modified to represent clinically and biologically relevant volumes.
- 8) The volumes are transferred to the dose planning process and considerations concerning bolus and priorities are discussed with the treatment planner.
- 9) Target definition and dose prescription used for the dose planning process is formally approved and documented.

## Normal tissues

### 29. The nomenclature (D), dose-volume constraints (C), and definition of volumes (D) should follow the guidelines of Table 1 and Appendix 1.

#### Literature and evidence review

##### Atlas of relevant normal tissues

Knowledge on normal tissue anatomy in the head and neck area can be acquired from the anatomy/-radiology literature. The definition of organs at risk does not always follow the strict anatomical or functional definition of an organ, but it is aimed for the organs at risk to be defined in a safe and operational manner, e.g. the location of the division from the spinal cord to the brainstem by bony landmarks. See Appendix 1 for delineation guidelines of OAR.

##### Dose volume constraints

The dose volume constraints relevant for head and neck cancer are listed below in Table 1. Data is mainly acquired from studies of conventional radiotherapy of adults without concomitant chemotherapy. Normal tissue tolerance can be different for other fractionation schedules, and the table is only applicable for fraction sizes of 2 Gy and below and is not applicable for children or hypo-fractionation. For some normal tissues, other models and other parameters are available. For other organs, no or limited data are available, and the dose-volume constraints are products of discussions and consensus among the members of the DAHANCA Radiotherapy Quality Assurance Group. The models and constraints are selected from the available evidence, with emphasis on being operational, simple, and relevant for the dose levels used in head and neck cancer radiotherapy.

For the optimization process, it is important to have in mind that the risk of toxicity is not dependent on a single dose-volume (DVH) parameter, but on a complex dose-volume interplay. All tissues should be spared to doses "as low as reasonable possible", - considering and prioritizing competing organs at risk.

*If over-dosage is unavoidable due to prioritization of target coverage, some guidance to over-dosage of critical normal tissues, with low risk of severe side effects, is provided. The violation of these constraints should be discussed with the patient, and consent should be recorded (BrainStem, SpinalCord and optical structures). The nomenclature follows Santanam, when applicable(39). Suffixes for L=left / R=right should be applied.  $D_{max}$  means  $D_{0,027\text{ cm}^3}$  ( $3 \times 3 \times 3\text{ mm}^3$ ). For delineation guidelines, see Appendix 1.*

**Table 1:** Dose Constraints

	Structure (alphabetically within)	Dose constrain	Dose constrain	Comments. Endpoint in bold	References
--	--------------------------------------	-------------------	-------------------	----------------------------	------------

	groups). Nomenclature and explanation	nt OAR [Gy]	nt PRV/ wc [Gy]		
ABSOLUTE	BrainStem	$D_{\max} \leq 54\text{Gy}$	$D_{\max} \leq 60\text{Gy}$	Treating $\leq 10\text{ cm}^3$ of the OAR to a maximum of 59 Gy results in a low risk of <b>neurological damage</b> . If over-dosage is unavoidable due to target coverage, it may be done. In the peripheral 3 mm rim of the brain stem, 64 Gy causes a low risk of neurological sequelae *.	Mayo(40) *Weber(41) *Debus(42)
	SpinalCord	$D_{\max} \leq 45\text{Gy}$	$D_{\max} \leq 50\text{Gy}$	Risk of <b>neurological damage</b> is estimated to 6 % for doses at 60 Gy. Limited over-dosage may therefore be allowed to achieve target coverage.	Kirkpatrick (43)
MUST	Chiasm OpticNerve_L OpticNerve_R	$D_{\max} \leq 54\text{Gy}$	$D_{\max} \leq 60\text{Gy}$	$D_{\max} \leq 55\text{ Gy}$ leads to a low risk of <b>visual disturbance</b> . Doses above 60 Gy leads to an estimated risk of above 7%. Dose constraint can be violated in order to achieve target coverage	Mayo(44)
	EyeBack_L EyeBack_R	$D_{\max} \leq 45\text{Gy}$	$D_{\max} \leq 50\text{Gy}$	<b>Retinopathy</b> is seen after doses as low as 30 Gy, and doses must be kept as low as possible. There is a volume effect and e.g. the lateral retina can be spared separately.	Jeganathan(45)
	EyeFront_L EyeFront_R (cornea, iris, lens)*	$D_{\max} \leq 30\text{ Gy}$	$D_{\max} \leq 35\text{ Gy}$	<b>Conjunctivitis, dry eye syndrome and cataract</b> . *The lenses have been removed from the list of OARs since it is contained in the anterior eye OAR and side effects may be treated. Even if constraints are not met for other parts of the optic pathways, the anterior eyes are worth sparing in order to preserve the eye in situ.	Jeganathan (45)
	Lacrimal_L Lacrimal_R (lacrimal gland)	$D_{\text{mean}} \leq 25\text{Gy}$	$D_{\text{mean}} \leq 30\text{Gy}$	<b>Dry eye syndrome</b> . Even if constraints are not met for other parts of the optic pathways, lacrimal glands are worth sparing in order to preserve the eye in situ. In case of severe dry eye syndrome, the eye must often be removed.	Jeganathan(45)

SHOULD	Brain	$D_{1ccm} < 58\text{Gy}$ $D_{max} \leq 68\text{Gy}$ Avoid hotspots.		At $D_{max}=72\text{ Gy}$ the risk of <b>necrosis</b> is 5% at 5 years. <b>Cognitive disturbances</b> may be seen at lower doses.	Su (46) Lawrence(47)
	Cochlea_L Cochlea_R	$D_{mean} \leq 45\text{Gy}$ and $D_{5\%} \leq 55\text{Gy}$	$D_{mean} \leq 50\text{Gy}$ and $D_{5\%} \leq 60\text{Gy}$	Risk of clinically relevant <b>hearing loss</b> may be as high as 15% at mean doses of 47 Gy when using concomitant cisplatin.	Bhandare(48) Chan(49) Hitchcock(50)
	Esophagus (cervical esophagus+ esophagus inlet muscle+ cricopharyngeal muscle)	$D_{mean} \leq 30\text{Gy}$		Limited data for radiation induced <b>swallowing problems</b> for the esophagus.	
	LarynxG (glottic larynx)	$D_{mean} < 40\text{ Gy,}$		Different available data for <b>swallowing problems</b> . No indications of a steep dose response curve.	Batth(51)
	LarynxSG (supraglottic larynx)	$D_{mean} < 40\text{ Gy}$		Different available data for <b>swallowing problems</b> . No indications of a steep dose response curve.	Batth (51)
	Mandible	$D_{max} \leq 72\text{Gy}$ $D_{mean} < 30\text{Gy}$ $V35\text{Gy} < 30\%$		<b>Osteoradionecrosis</b> . Limited data.	Eisbruch (52) Aarup-Kristensen(53) Van Dijk (54)
	OralCavity	$D_{mean} \leq 30\text{Gy}$		<b>Xerostomia, dysphagia, and mucositis</b>	Hawkins (55) Dean(56) Hansen(57)

	Parotid_L Parotid_R	1) Contralateral parotid: $D_{\text{mean}} \leq 20\text{Gy}$ 2) Both parotids: $D_{\text{mean}} \leq 26\text{Gy}$	<i>Xerostomia</i>	Deasy (58)
	PCM_Low (lower pharyngeal constrictor)	$D_{\text{mean}} < 55\text{ Gy}$	Different available data for <b>swallowing problems</b> . No indications of a steep dose response curve.	Batth (51)
	PCM_Mid (middle pharyngeal constrictor)	$D_{\text{mean}} < 55\text{ Gy}$	Different available data for <b>swallowing problems</b> . No indications of a steep dose response curve.	Batth(51)
	PCM_Up (upper pharyngeal constrictor)	$D_{\text{mean}} < 55\text{ Gy}$	Different available data for <b>swallowing problems</b> . No indications of a steep dose response curve.	Batth (51)
	Pituitary	$D_{\text{mean}} \leq 20\text{Gy}$	No certain threshold. The risk of <b>hormonal disturbances</b> increases at $>20\text{ Gy}$	Darzy(59). Paulissen(60)
	Submandibular_L Submandibular_R	$D_{\text{mean}} \leq 35\text{Gy}$	<b>Xerostomia</b>	Deasy(58)
	Thyroid	$D_{\text{mean}} \leq 40\text{ Gy}$	No specific threshold for <b>biochemical hypothyroidism</b>	Rønjom (61) Boomsma (62)
CAN	Carotid_L Carotid_R	$D_{\text{max}} \leq 40\text{ Gy}$	Should be spared to avoid <b>stenosis and cerebral ischemia</b> in case no elective volume is irradiated e.g. T1a/b glottic cancer or ipsilateral radiotherapy	Choi (63)
	BuccalMuc_L/ R	$D_{\text{mean}} \leq 30\text{Gy}$	<b>Xerostomia</b> (and perhaps mucositis)  Data only available as a part of oral cavity	Dean (56)  Hawkins(55)

	Buccal mucosa			
	Lips	$D_{\text{mean}} \leq 20\text{Gy}$	Mucositis, Cheilitis	RTOG 1016
	Hippocampus	$D_{40\%} < 7.2\text{Gy}$ [EQD2] (i.e. $< 11\text{Gy}$ on 33fx with $\alpha/\beta=3$ )	Risk of <b>poor memory</b> at 11% and 66% at doses below and above constraint. The consequences for other OARs resulting from hippocampal sparing should be monitored carefully at dose optimization due to the very low constraint.	*Gondi (64)

**ABSOLUTE:** Organs of critical importance that must be prioritized over target coverage, as a rule

**MUST:** Serial organs that must be delineated, but not necessarily prioritized over target coverage.

**SHOULD:** Organs at risk with some evidence for sparing, and OAR with serious but manageable toxicity.

**CAN:** Poor evidence, uncertain endpoints or manageable toxicity. Organs may be delineated according to local guidelines/research projects.

### Dose constraints for palliative treatment

In case of disseminated disease, poor performance status etc. where long term survival or disease control may be unlikely, a hypofractionated treatment may be administered using e.g. 4 Gy fractions to e.g. 52 Gy. In that case, dose constraints should be modified using an  $\alpha/\beta=3$ :

	Structure (alphabetically within groups). Nomenclature and explanation	Dose constraint OAR [Gy]	Dose constraint PRV/wc [Gy]
ABSOLUTE	BrainStem	$D_{\text{max}} \leq 43\text{Gy}$	$D_{\text{max}} \leq 46\text{Gy}$
	SpinalCord	$D_{\text{max}} \leq 38\text{Gy}$	$D_{\text{max}} \leq 41\text{Gy}$
MUST	Chiasm OpticNerve_L OpticNerve_R	$D_{\text{max}} \leq 43\text{Gy}$	$D_{\text{max}} \leq 46\text{Gy}$

EyeBack_L	$D_{\max} \leq 38\text{Gy}$	$D_{\max} \leq 41\text{Gy}$
EyeBack_R		

**Table 2:** Dose constraints for treatment using 4 Gy/ fraction (equivalent to EQD2 in table 1,  $\alpha/\beta=3$ , physical dose rounded). Dose constraints for these OAR's arise primarily from old 2 Gy/ fx data and can be easily converted. Other, newer constraints cannot be converted the same way.

### Reirradiation: Optimization and suggestions for dose constraints

Due to previous dose deposition, adherence to the above mentioned constraint may be difficult in case of reirradiation. The cumulative doses of the combined initial radiotherapy and re-irradiation must be considered for all late effects. Therefore, a cumulated dose plan of previous and present treatment must be made (see below) in order to evaluate risks and benefits.

The spinal cord and brain stem are spared according to DAHANCA constraints if possible. The effects of fractionation, according to the LQ model assuming an  $\alpha/\beta=3$  and a recovery of 25% of primary dose after 6 months (65) may be used in order to obtain target coverage.

#### Calculation example

Primary radiotherapy: 2 years ago. 66 Gy in 33 fraction with integrated boost. Spinal cord dose  $D_{\max}$  36 Gy

Current radiotherapy: 60 Gy in 50 fractions. Spinal cord dose  $D_{\max}$  30 Gy

Prior: Sp.c. EQD2:  $36 * ((36/33)+3)/(2+3) * (1-0,25) = 22 \text{ Gy}$

Current Sp.c. EQD2:  $30 * ((30/50)+3)/(2+3) = 22 \text{ Gy}$

Cumulative Spinal cord EQD2 =  $22+22=44 \text{ Gy}$  i.e. safe treatment irrespective of  $D_{\max}$  position.

The carotid arteries: ALARA. EQD2 < 119 Gy has been suggested (66).

### Cumulated treatment plan for evaluation and planning of re-irradiation

No evidence-based consensus exists on how to accumulate doses. Accumulating doses on treatment plans often made years apart, requires that many factors are taken into account. The tumour on the initial dose plan has disappeared, many patients have been through surgery, some including reconstructive procedures, and some lost or gained weight and stature. Nevertheless, an attempt to accumulate doses may greatly improve the evaluation of dose plans, aiding decisions as to – whether dose outside the target should be redistributed or whether the treatment is feasible altogether. Rigid or well-defined structures, such as the spinal cord, may be easier to evaluate than soft tissues such as the oral cavity. The most informative dose accumulation is probably done using deformable image registration with deformation of the initial dose matrix onto the new scan. Further information can be added by correcting doses for repair and fractionation effect (67). As OARs receive less than target dose this should be done irrespective of fractionation. Great care should be given to areas with anatomical changes and steep dose gradients as any attempt to do dose summation will be especially hampered by uncertainties

- 30. A cumulated treatment plan, even corrected for recovery and fractionation, may be beneficial for the planning of re-treatment, but physical and biological uncertainties should be considered (D)**

## Radiotherapy dose planning

- 31. Dose planning should attempt to comply with the tolerance levels for target-coverage and normal tissue sparing described in Table 2 (D)**

### Literature and evidence review

The treatment planning process for radiotherapy consists of a series of patient-related procedures and machine work tasks that eventually result in a treatment plan that enables a radiation dose prescription to be applied effectively for tumour control, and safely for the patient. This entails a long string of hardware and software equipment that is involved in application of photon beams, electron beams, and particles, such as protons.

Economic issues are strongly involved in radiation treatment, and thus treatment planning and delivery is not only based on clinical experience and scientific evidence, but also on the performance and availability of technical equipment from commercial manufacturers. Therefore, Oxford-levels of recommendation are considered D, however, due to patient safety and legal issues, radiotherapy is carried out at the highest level of approval by authorities.

### Non-coplanar fields

The use of non-coplanar fields or -partial arcs should be used with the awareness of added complexity in quality assurance of patient positioning as CBCT's can't be used to verify couch position after shift, but 2D-kV images/ surface guidance should be used, and couch position quality assured.

### Air within the target

In case there is air within the target, any influence of increase or decrease of the volume should be evaluated and ideally incorporated in the treatment plan optimization and evaluation, e.g. examining the influence of adding/ subtracting water or air.

### Bolus/ target close to skin

When the target volume is close to the skin surface, the use of a bolus is often recommended to ensure adequate superficial dose delivery, thereby enhancing treatment efficacy for superficial tumors.

It is a clinical decision whether or not to apply bolus; however, this decision should be based on a dosimetric understanding: When using static field RT, the beam direction plays an important role since the build-up effect

and the lack of lateral scatter in the skin surface is directly linked to the beam angle. When using VMAT, beam intensity becomes important, as the need for bolus relies on the amount of fluence planned in the specific directions.

The bolus should be as close to the skin as possible, and air gaps between the skin and bolus should be minimized to improve the dose robustness and effect of the bolus(68).

If there is tumor involvement of the skin, bolus should be used to ensure dose to the GTV.

If the CTV1 is in the skin area, typically the outermost 3 mm, it is often necessary to use a bolus to achieve the required dose. If involvement near the skin is not suspected, the CTV1 and CTV2 volume should be cropped away from the skin, and a bolus can be avoided.

If the CTV3 approaches the skin area, it is often recommended to crop the target and avoid a bolus.

Bolus should be matched to the patient and, when placed on the patient, verified using CBCT or surface scanning. The thickness depends on the clinical case and treatment technique. However, a thicker bolus is often better in dose capabilities but less flexible. A 3D printed bolus offers both a high degree of flexibility and good dose capabilities.

### **Dose prescription**

The prescribed dose for a target (CTV) is the mean dose.

### **Dose calculation**

For *photon and proton* treatment, the mean dose must be the prescribed dose. Dose in CTV2<sub>only</sub> (CTV2 minus CTV1) and CTV3<sub>only</sub> (CTV3 minus CTV2) must be as close to prescription dose, for the specified volume, as achievable.

CTV1 must be covered with 95%-107% of the prescribed dose. CTV2 and CTV3 must be covered with 95% of the prescribed doses. The 95% isodose curve for PTV1, PTV2, and PTV3 must be as close to the delineation of PTV1, PTV2, and PTV3 respectively, as achievable. Adherence to this is defined by QA measures, see Table 2.

A maximum volume of 1.8 cm<sup>3</sup> in the patient may receive >107% of the prescribed dose to CTV1.

Dose calculation must take differences in patient density into account. This applies to both primary and scattered radiation.

For *electrons* the minimal dose for PTV must be 92.5% of the prescribed dose, and the maximum dose should be <107% of the prescribed dose. Dose calculation for electrons should preferably be based on density information of a CT scanning, but for tumours close to the skin, a manual calculation may be performed.

Simultaneous integrated boost (SIB) is used as the standard technique, with different dose levels for CTV1, CTV2 and CTV3, but with all volumes treated at each fraction. The total dose to the low-risk elective regions has therefore been increased from 46 Gy (2 Gy/fx) to 50 Gy (1.5 Gy/fx) and 56 Gy (1.0 Gy/fx), see Appendix 2.

### **Prioritization of treatment goals**

Optimization algorithms and dose planning systems requires a prioritization of the treatment goals. The prioritization listed below is recommended for maximal clinical benefit, but individual prioritization may differ according to patient wishes and the clinical situation. The OARs are not listed by priority within groups.

#### **1. Critical normal tissues, potentially lethal complication**

SpinalCord  
BrainStem

#### **2. Target coverage**

GTV  
CTV1

#### **3. Critical serial normal tissues**

EyeFront  
Chiasm  
EyeBack

#### **4. Target coverage**

CTV2  
CTV3  
PTV1  
PTV2  
PTV3

#### **5. Sensitive normal tissue**

Not prioritized  
Brain  
Cochlea  
Esophagus  
LarynxSG  
LarynxG  
Mandible  
OralCavity  
Parotid  
Version 2.0

PCM  
Pituitary  
Submandibular  
Thyroid  
Carotid  
BuccalMuc  
Lips  
Hippocampus

## 6. Avoid overdosage of CTV2 and CTV3

### 7. Plan complexity

The use of added fields, especially non-coplanar fields and added modulation should be evaluated, and if the benefits does not significantly outweigh the disadvantages in dose uncertainty, a less complex treatment plan should be used.

## Complex dose planning

### Literature and evidence review

In some cases a target ca- not be covered by dose without violating constraints for critical normal structures. In these cases, a compromise between target coverage and normal tissue doses should be discussed with the patient. The present guidelines do not contain any advice or criteria for HOW to prioritise, but only for reporting and quality assurance. DAHANCA has successfully carried out QA of treatment plans and analysed recurrences. This is difficult or even impossible if compromises have been made (69), as many (unknown) strategies has been applied. It is therefore necessary for these analysis that the treatment priorities are evident. This can be ensured by:

- Creating a "according to guidelines" CTV. A CTV created by adhering to the present guidelines without prioritizing OAR's
- A "by necessity" CTV: A CTV that contains the part of the target that is **prioritized** above some critical OAR's

In case a comparative treatment plan is made for deciding if a patient could benefit from proton radiotherapy, it is important to define the priorities, i.e. which OARs should be prioritized over target coverage, and which constraints should be used, before treatment planning.

### Terminology

CTV "according to guidelines": CTV1, CTV2, CTV3 (as normal)


CTV "by necessity": CTV1\_prio, CTV2\_prio

OAR\_prio could be defined in the same way.

PTV should be defined geometrically. A non-isometric margin could be used, if it is reflected in the setup/ IGRT strategy (e.g. a lower tolerance at setup in a certain direction).

Volumes should be prioritized as follows

- 1: Critical normal tissues (OAR\_prio)
- 2: GTV, CTV\_prio
- 3 Other normal tissues
- 4: Other CTV's
- 5: PRV, PTV, wcOAR and wcCTV (wc= worst case)



**Figure 3** Example of target definition and nomenclature. GTV: Red translucent. CTV1\_prio: Magenta. CTV1: Blue. Optic nerve: Yellow and orange. GTV is suspected to involve the medial wall of the orbita and the left sphenoid sinus but not the septum. Therefore, the CTV1\_prio includes the orbital content and posterior bone but not the right part of the sphenoid bone or nasal cavity, and it is prioritised above the left optic nerve (OpticNerve\_L). CTV1 includes GTV with a geometric margin of 5 mm, modified not to include the right uninvolved nasal cavity, and is prioritised below the right optic nerve (OpticNerve\_R\_prio). The dose distribution (not shown) is expected to include the left optic nerve above constraint but to spare the right optic nerve. The clinical goals are visible from the modification of the volumes, and the treatment plan can be quality assured for CTV1\_prio, and any recurrence can be analysed with respect to both volumes and doses

Non-standard normal tissue constraints could be used in order to treat the patient with curative intend with low risk of serious side effects:

Table 3 Non-standard normal tissue constraint

	Structure Nomenclature and explanation	Dose constraint OAR [Gy]	Dose constraint PRV/wc OAR [Gy]	Factors of importance when considering treatment planning compromises. Endpoint in bold	References
	BrainStemCore	$D_{\max} \leq 54\text{Gy}$	$D_{\max} \leq 60\text{Gy}$	Treating $\leq 10\text{ cm}^3$ of the OAR to a maximum of 59 Gy results in a low risk of <b>neurological damage</b> . If over-dosage is unavoidable due to target coverage, it may be done. In the peripheral 3 mm rim of the brain stem, 64 Gy causes a low risk of neurological sequelae *. Brainstem constraints may be used for C1 SpinalCord, as this is anatomically brainstem.	(40) (41) (42)
	BrainstemSurface	$D_{0,5\text{ccm}} < 64\text{Gy}$			EP TN (70)
	SpinalCord*	$D_{\max} \leq 45\text{Gy}$	$D_{\max} \leq 50\text{Gy}$	Risk of <b>neurological damage</b> is estimated to 6 % for doses at 60 Gy. Limited over-dosage may therefore be allowed to achieve target coverage. *SpinalCordC1 is sometimes considered having the same constraint as brainstem (71)	(43)
	SpinalCord_Core	$D_{2\%} < 54\text{Gy}$		4% risk of $Gr \geq 2$ late neurological toxicity (40% if exceeded)	(72)
	SpinalCord_Surface	$D_{2\%} < 64\text{Gy}$			
	Chiasm	$D_{\max} \leq 58\text{Gy}$			(73)

	OpticNerve_L	$D_{\max} \leq$			(73)
	OpticNerve_R	58Gy			

### Normalisation/prescription – complex planning

If there is a significant difference between CTV and CTV\_prio, dose should be normalized to CTV\_prio. Dose to CTV should also be reported..

## Treatment

### Literature and evidence review

Like the treatment planning process for radiotherapy described above, radiation treatment delivery is defined by a series of patient-related procedures and technical aspects related to accelerators and additional equipment. Therefore, the Oxford-level of recommendation is considered D. However, due to patient safety and legal issues, radiotherapy is carried out at the highest level of approval by authorities.

According to ICRU, the dose rate must be at least 0.1 Gy/min inside the CTV in photon radiotherapy.

### Image guidance

Patient positioning should be verified with CBCT-scans according to local guidelines. Tolerances and imaging frequency should be defined locally with respect to local PTV and PRV margins originating from measurements of random and systematic uncertainties in the whole process of treatment preparation and delivery(74).

The anatomical structures used for matching must be defined with respect to target localisation. For example, emphasis must be put on more cranial structures for nasopharyngeal tumours than for hypopharyngeal tumours. The 'region of interest' (ROI) for the matching process must also take the extent of the elective areas into account. Match structures with limited internal movements should be chosen, e.g. not the hyoid bone, but preferably the cervical spine. Soft tissue matching is often possible when CBCT scans are available. The ROI must be chosen to include both target and critical normal tissue. Both automatic and manual match must be visually verified according to bony anatomy and visible soft tissue.

In case of non-adherence to pre-specified tolerances, target coverage and normal tissue sparing should be prioritized as described above, and the reasons for non-adherence should be documented.

### Re-planning

It should be continuously evaluated whether patient anatomy and the effectiveness of the immobilisation device change to a degree that may have significant implication on the dose distribution. In case of larger changes, an evaluation of the dosimetric consequences should be performed and the need for a new immobilisation and/ or treatment plan must be evaluated. Re-planning must always take place in case of risk of critical normal tissue overdose or insufficient high dose target coverage. If dose evaluation and especially

dose planning for adaptive plan is performed on CBCT or virtual CT, these calculations must be quality assured

## Special considerations for proton therapy

Potential candidates for proton therapy are identified at the local departments of oncology, often after a comparative treatment plan, i.e. comparison of two treatment plans using protons and photons, respectively. The dosimetric differences are quantified and applied to normal tissue complication models (NTCP) to estimate a potential benefit of proton therapy, if available. If it is decided that the patient should be offered referral to the Danish Centre for Particle Therapy (DCPT), and the patient accepts, further planning will take place at DCPT. The patients are referred to the local department of oncology for follow-up after end of treatment.

The principles regarding dose prescription, definitions of clinical target volumes (CTV1, CTV2, or CTV3), target selection, normal tissue definition, nomenclature, and normal tissue constraints are applicable for both photons and protons. Several factors are qualitatively different between proton and photon planning as described below. The advantages, as well as disadvantages of proton therapy are well illustrated by the depth-dose curve and the Bragg peak.

### Preparation and scanning

There are special considerations regarding homogeneity and blunt edges of the immobilisation devices. The CT-scanners must be calibrated and optimized for the translation of HU to proton stopping power, using e.g. dual energy CTs. Nevertheless, mono energetic, non-calibrated CTs or even synthetic CT based on diagnostic MRI scans can be used for comparative treatment plans. The dosimetric differences of the comparative dose plan should be quantified using differences in dose and expected NTCPs of specific OARs if models are available.

### Dose planning

Proton therapy planning includes other solutions than photon therapy regarding choice of field angles, number of fields, techniques for skin coverage, and lateral penumbra. The final treatment plan at DCPT, as well as comparative dose planning, requires special skills and training defined by the DCPT.

The PTV concept is not an optimal solution for uncertainties from immobilization, scanning, setup errors, and dose calculation in proton therapy. In dose optimization, CTV coverage and critical normal tissue sparing are ensured in multiple 'worst-case scenarios' of setup errors and range uncertainties, referred to as robust optimization. Dose to CTV and dose limits to OARs are prescribed and reported for the nominal plan, i.e. the robustly optimized dose plan with no introduced errors.

DCPT will ensure that proton treatment plan guidelines are updated.

The CTV in head and neck cancer is often located close to the skin. The lowest possible energy delivered by

the cyclotron at DCPT is 70 MeV, which is equivalent to a Bragg peak depth of 4 cm. Therefore, a range shifter (a water equivalent plastic plate) is introduced between the snout and the patient. This reduces the energy and deposits the dose closer to the surface. Unfortunately, the range shifter also limits the space around the patient and restricts the possible field directions as well as increases the spot sizes, whereby the lateral penumbra is degraded.

### Treatment

Patient positioning is very similar to photon treatment. CBCTs are used for correction of translational and rotational errors. Nevertheless, proton therapy requires greater attention to changes in depth and density, e.g. shoulder position, immobilization devices and anatomical changes, since the energy deposition of protons relies heavily on these parameters. The duration of proton therapy is increased. Often the patients are immobilised for >30 minutes.

## Treatment prolongations

All fields must be treated at all fractions. Patients treated with 6 fractions per week must receive a single fraction Monday to Friday and the sixth fraction should be administered during the weekend or as an extra fraction on a weekday. An interval of at least 6 hours between fractions must always be ensured. For patients receiving 10 fractions per week, two daily fractions with an interval of at least 6 hours are used.

Before the first treatment interruption (e.g. a weekend), at least 4 Gy should be administered, and similarly, not less than 4 Gy should be administered after a weekend.

In case of treatment prolongation, either acutely e.g. due to comorbidity, or expected, e.g. public holidays, the overall treatment time, from first to last fraction, should be maintained if possible. The missing fraction(s) must be administered as soon as possible and ideally within a week, if clinically applicable. This can be done by delivering an extra fraction during weekends or on the day of a planned fraction (but at least 6 hours apart).

Considering acute toxicity, treatment breaks should not be compensated with more than one extra fraction per week, and no more than 13 consecutive treatment days. Furthermore, no more than 3 days of double fractionation must take place within 2 weeks for conventional fraction sizes.

To compensate for longer treatment breaks, hyper-fractionation and dose escalation may be worth considering (75).

## Radiotherapy quality assurance

### 32. Dose planning should strive to achieve the tolerances for target-coverage and normal tissue sparing mentioned in table 2 (D)

#### Literature and evidence review

Treatment methods must be quality assured and reported in clinical trials. QA can be divided into three steps:

**Step 1:** Preparation including writing guidelines, dose audits, and delineation workshops.

**Step 2:** Daily QA: Technical QA of the performance of the accelerators, verification of delineation, dose plans, and setup procedures.

**Step 3:** Follow-up on the given treatments; reporting, sampling, and evaluation according to predefined criteria of minor and major deviations.

### **Preparation**

The principles of technical QA in DAHANCA refer to "Practical Guidelines for the Implementation of a Quality System in Radiotherapy" from the European Society for Therapeutic Radiology and Oncology (ESTRO), "Comprehensive QA for Radiation Oncology", Reports of AAPM Radiation Therapy Committee Task Group 40, and "Absorbed Dose Determination in Photon and Electron Beams", Technical Report Series 398, from the International Atomic Energy Agency (IAEA).

It will be described below how the correct treatment of head and neck cancer is ensured under the auspices of DAHANCA. Also, local guidelines must exist in all centres to ensure adherence to the national guidelines by DAHANCA.

### **Dose audit**

The path from CT scanning, dose planning, and treatment delivery is complex, and all steps must be verified. Nevertheless, transitions from one step to another may also introduce errors that may escape a stepwise QA. One way to assure that all steps and transitions are retained is by performing a dose audit: A dose audit includes treating a standardized phantom according to specified guidelines to certain doses. Dose to the phantom is measured and compared to the dose plan produced at the centre. It is recommended that an external dose audit is performed at least every 5 years under the auspices of the DAHANCA Radiotherapy Quality Assurance Group.

### **Delineation workshops**

The basis of dose planning is the delineation of the tumour and clinical target volume. Delineation guidelines for the OARs and CTVs contained in the present guidelines are aimed at increasing consistency and comparability between patients and centres. Nevertheless, no gold standard exists, and delineation practices must be continuously evaluated through participation in national workshops. National delineation workshops will be arranged every 3 years through the DAHANCA Radiotherapy Quality Assurance Group.

### **Daily quality assurance**

A guideline for daily QA must be present at all centres.

### **Delineation verification and approval**

Delineation of targets and normal tissues must be approved by a trained specialist. Delineation must, as a rule, follow the present guidelines, and deviations from the guidelines should be described in the medical records.

### **Dose planning control and approval**

Version 2.0

All dose plans must be controlled by an independent dose planner or a physicist. Prescribed dose and target coverage on all CT slices, as well as dose to the normal tissues, must be verified.

### Imaging calibration

A procedure for the calibration and QA of the localisation of imaging and treatment isocentre must be available in all centres.

### Follow-up

A continuous adaptation of QA and guidelines to technical and clinical developments is essential. Reports of the delivered treatment are therefore important.

### Reports of radiotherapy

Prescribed dose to CTV1, CTV2 and CTV3, as well as date of first and last fraction should be reported in the "Primary Treatment" charts of the DAHANCA data-base.

### Central quality assurance

For all patients participating in clinical protocols with planned central QA, dose plans in the DICOM format must be electronically transferred to a central data base according to specific guidelines.

### QA Audits

According to pre-defined agreements, QA audits are performed in all DAHANCA protocols, either by sample or for the entire cohort. Appointed experts will audit the clinical data as well as the treatment plans. The evaluations will be graded according to any degree of protocol deviation as minor or major. Major deviations are defined as deviations with potential influence on survival.

**Table 4** QA Parameters

	Per protocol	Minor deviations	Major deviations
Dose prescription for the CTV1	66, 68, 70, 76 Gy		
Mean dose to CTV1	±1 %	±2 %	
Minimum dose to CTV1	95% of dose to 99% of CTV1, and 90% of dose to the last 1 % of CTV1	95% of dose to 98% of CTV1, and 90% of dose to the last 2 % of CTV1	< 95% of dose to ≥2% CTV1
Minimum dose to PTV1 (skin excluded)	95% of dose to 98% of PTV1, and 90% of dose to the last 2 % of PTV1	95% of dose to 95% of PTV1, and 90% of dose to the last 5 % of PTV1	< 95% of dose to ≥5% of PTV1
Maximal dose to > 1,8 cm <sup>3</sup> (D <sub>1.8cm<sup>3</sup></sub> )	≤107% of CTV1 dose	≤ 110% of CTV1 dose	> 110% of CTV1 dose

Maximal dose to spinal cord ( $D_{0.027 \text{ cm}^3}$ )	$\leq 45 \text{ Gy}$	45-50 Gy	$> 50 \text{ Gy}$
Maximal dose to PRV spinal cord / wc spinal cord ( $D_{0.027 \text{ cm}^3}$ )	$\leq 50 \text{ Gy}$	50-55 Gy	$> 55 \text{ Gy}$
Maximal dose to brain stem ( $D_{0.027 \text{ cm}^3}$ )	$\leq 54 \text{ Gy}$	54-59 Gy	$> 59 \text{ Gy}$
Maximal dose to PRV brain stem/ wc brain stem ( $D_{0.027 \text{ cm}^3}$ )	$\leq 60 \text{ Gy}$	60-65	$> 65 \text{ Gy}$
Length of the treatment course	Accelerated radiotherapy (6 and 10 fx/week): $\leq 41$ days.	Accelerated radiotherapy (6 and 10 fx/week): 42-46 days	Accelerated radiotherapy (6 and 10 fx/week): $> 47$ day
	5 fx/weeks: $\leq 48$ days	5 fx/week: 49-53 days	5 fx/week: $> 54$ days

## Guidelines for elective lymph node irradiation

The recommended elective nodal volumes irradiated within the DAHANCA guidelines, are highly dependent on the T-site and –extension. This is in contrast with e.g. [Biau], where the nodal stage also defines the elective volumes. DAHANCA have failed to find any clinical data to support an expansion of the elective volumes beyond what is mentioned below for specific tumour sites, but some volumes need a clarification:

### Level V

The only indication for level V irradiation is involvement of the nasopharynx, or involvement of level V itself. I.e. posterior level II-IV or level X involvement is not an indication for adding level V to the elective volume.

### Retropharyngeal nodes

Retropharyngeal nodes are included in case of nasopharyngeal or posterior oropharyngeal wall involvement. In these circumstances they are always included bilaterally. In case of limited retropharyngeal node involvement, in case of lateralized oropharynx cancer (see below), ipsilateral irradiation only may be sufficient.

## Guidelines for specific tumour sites

### Oral Cavity

*Anatomy:* The oral cavity includes buccal mucosa, gingiva, hard palate, anterior 2/3 of the tongue, and floor of mouth. Lateral tumours are defined as tumours of the buccal mucosa, gingiva and retromolar trigone, with no involvement of contralateral nodes. Midline tumours are defined as tumours of the tongue, floor of mouth, and hard palate, *and any tumours with involvement of these structures*. Midline tumours have the propensity of

bilateral nodal involvement. Drainage to the lymphatic system from the anterior tongue rarely spreads to level III and IV without involvement of proximal nodes.

Primary treatment is described in the national guidelines (dahanca.dk). Shortly, the mainstay of treatment is surgery for resectable tumours whenever a good functional and cosmetic result can be expected.

Postoperative radiotherapy is added in case of non-radical surgery (R1 or R2) in N or T-site, pN2-3, and/or pT3-4, or any N stage with ENE. Target delineation is often greatly improved when the operating surgeon takes part in the procedure.

### **Radical radiotherapy:**

**CTV1:** Primary tumour (GTV-T) and involved lymph nodes (GTV-N) with an isotropic margin of 5 mm. Larger margins should be used for ill-defined tumours and margins should be cropped for air and natural anatomical barriers such as bone, unless bone involvement is evident.

**CTV2:** GTV-T and -N with an isotropic margin of 10 mm. Margins should be cropped for air and natural borders such as bone, unless bone is adjacent to the GTV. Here, 2 mm cortical bone is included for T1 and T2 tumours. The CTV2 should not be cropped in case of T3 and T4 tumours adjacent to bone. CTV2 can be individually expanded to include high-risk anatomical areas, e.g. the ipsilateral or whole tongue in case of tongue involvement or ipsilateral floor of mouth.

**CTV3:** Midline tumours are treated with bilateral elective regions, and lateral tumours with ipsilateral elective regions. Ia is included if anterior part of floor of mouth, gingiva, tongue, or lower lip is involved. Elective nodal regions are:

- N0: level Ib, II, III
- N1-3: level Ib, II, III. Elective regions are extended at least 2 cm cranially and caudally of GTV-N. If extension to nearby muscle is suspected, the entire muscle is included at least 2 cm above and below GTV-N.

### **Postoperative radiotherapy:**

**CTV1:** Macroscopic tumour (R2), microscopically non-radically resected (R1), or areas of ENE, with an isotropic margin of 5 mm. Larger margins should be used for ill-defined tumours, and margins should be cropped for air and natural anatomical barriers such as bone, unless bone involvement is evident

**CTV2:** CTV1 with an isotropic margin of 5 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers such as bone.

In case of an absent CTV1, i.e. in radically resected patients (R0), CTV2 is defined as the pre-operative GTV with at least 10 mm margin. In case of uncertainties as to the localization of involved nodes, or if the involved nodes are not identified on a pre-operative scan, the entire involved level is included. Due to the difficulties of

irradiating a T-site recurrence, the T-site should be included in CTV2, even if the indication for postoperative radiotherapy is in the N-site e.g. non-radically removed nodes, ENE, or N2-N3.

**CTV3:** Remaining surgical bed and elective nodal levels without a margin. As a rule, bilateral irradiation of elective levels is used, but ipsilateral irradiation only is used in case of primaries in the cheek, lateral gingiva, and retromolar trigone without invasion of the floor of mouth, base of tongue, or hard palate, as well as absence of contralateral pathological nodes. Ia is included if anterior part of floor of mouth, gingiva, tongue, or lower lip is involved.

Note: If the indication for radiotherapy is due to R1-R2 resection in the T-site alone, no elective nodal irradiation should be performed for pT1-2.

Elective nodal regions are

- pN0: level Ib, II, III.
- pN1-3: level Ib, II, III. Elective regions are extended at least 2 cm cranially and caudally of GTV-N. If extension to nearby muscle is suspected, the entire muscle is included at least 2 cm above and below GTV-N.
- In case of involvement of macroscopic cranial nerve, the nerve is included to the base of skull.

## Nasopharynx

*Anatomy:* The nasopharynx is limited by the choanae (anteriorly), pre-vertebral muscles (posteriorly), medial border of the parapharyngeal space (laterally), skull base (superiorly), and caudal border of C1 (inferiorly).

The target is defined by both a CT and MRI scan.

**CTV1:** Includes the primary tumour (GTV-T) and involved nodes (GTV-N) with an isotropic margin of 5 mm. Larger margins are used in case of a poorly defined primary, and margins should be cropped for air and natural barriers such as bone, unless bone involvement is evident.

**CTV2:** GTV-T and -N with an isotropic margin of 10 mm, cropped for air and natural barriers such as bone, unless bone is involved. Furthermore, CTV2 includes

- A) The remaining nasopharynx
- B) Skull base with bilateral foramina ovale, foramina rotunda and foramina lacera
- C) Inferior 5-10 mm of the sphenoid sinus, (the entire sinus in case of involvement)
- D) Posterior 5 mm of nasal cavity and maxillary sinus (the entire sinus in case of involvement)
- E) Anterior one third of clivus, (the entire clivus in case of involvement)

F) The ipsilateral cavernous sinus if invasion is suspected

An example of CTV2 in nasopharynx cancer is illustrated in Appendix 5.

### **CTV3: Elective nodes**

N0: Bilateral level II-III, Va, VIIb (retro-styloid) , VIIa (retropharyngeal) and the parapharyngeal space.

The parapharyngeal space (PPS) is an inverted pyramidal fat-filled space in the lateral suprahyoid neck, with its base attaching to the skull base and the apex extending to the superior cornu of the hyoid bone.

Anatomically, PPS is bordered anteriorly by the pterygo-mandibular raphe, anterolaterally by the medial pterygoid muscle, and posterolaterally by the deep lobe of the parotid gland)(76).

N+: Includes N0 volume plus ipsilateral level IV and Vb. Level Ib is included in case of invasion of the submandibular region, oral cavity. or anterior nasal cavity. Ib may be included ipsilaterally only, in selected cases. Elective regions are extended at least 2 cm cranially and caudally of GTV-N. If extension to nearby muscle involvement is suspected the entire muscle is included at least 2 cm above and below GTV-N.

## **Oropharynx**

*Anatomy:* Oropharynx is limited by the anterior faucial pillars, macroscopic taste buds (papillae vallatae), soft palate including uvula, and vallecula. The laryngeal surface of the epiglottis belongs to the supraglottic region. Oropharynx thereby includes the posterior third of the tongue, vallecula, tonsils, tonsillar pillars, posterior pharynx and soft palate.

### **Radical radiotherapy**

**CTV1:** Includes the primary tumour (GTV-T) and involved nodes (GTV-N) with an isotropic margin of 5 mm in all directions. Larger margins should be used for ill-defined tumours and margins should be cropped for air and natural barriers such as bone, unless bone involvement is evident.

After diagnostic tonsillectomy, the tonsillar fossa and pillars are considered as the CTV1 to a depth of 5 mm. The clinical examination is very important in the evaluation of the extent to soft palate and especially the base of tongue. Base of tongue tumours are often difficult to depict on CT or MRI and it is often necessary to include a large part of the base of tongue in CTV1 or CTV2.

**CTV2:** GTV-T and -N with an isotropic margin of 10 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers such as bone. CTV2 can be individually expanded to include high risk areas such as the entire or ipsilateral base of tongue in case of base of tongue primary, or invasion from an adjacent tonsillar primary.

**CTV3:** Tumours confined to the tonsillar fossa and tonsillar pillars are considered lateral tumours and are treated with ipsilateral radiotherapy. Ipsilateral radiotherapy can be used in case of ipsilateral retropharyngeal nodal involvement if the primary does not involve midline structures. Tumours arising in, or extending to, the

base of tongue, soft palate, or posterior pharyngeal wall are considered midline tumours and should be treated with bilateral elective irradiation.

Elective nodal regions are:

- N0: Level II, III. The retropharyngeal nodes are included in case of posterior pharyngeal wall involvement and level Ib is included in case of oral cavity involvement. Ib may be included ipsilaterally only, in selected cases
- N1-3: Level II, III. Level IV on the side of nodal involvement. Elective regions are extended at least 2 cm cranially and caudally of GTV-N. If extension to nearby muscle involvement is suspected, the entire muscle is included at least 2 cm above and below GTV-N. The retropharyngeal nodes are included in case of posterior pharyngeal wall involvement and level Ib is included in case of oral cavity involvement. Ib may be included ipsilaterally only, in selected cases.

### Postoperative radiotherapy

Indication for postoperative radiotherapy after primary surgery is done in accordance with the DAHANCA 34 protocol:

- T-site: < 2 mm free margin or pT3/ pT4 tumours
- N- site: more than 2 positive nodes, or 2 node metastases both >1 cm. Extranodal extension (ENE). Less than 10 removed nodes in each side of the neck dissection.

**CTV1:** Any macroscopic tumour (R2), areas of non-radical surgery (R1) or ENE, plus an isotropic margin of 5 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers such as bone.

**CTV2:** Includes CTV1 with an isotropic margin of 5 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers such as bone cropped for air and at natural barriers such as bone.

In case of an absent CTV1, i.e. radiotherapy after radical surgery (R0), CTV2 includes pre-operative GTV with a minimum 10 mm margin. If the indication for postoperative radiotherapy is due to N-site alone, the primary tumour volume (R0) is included in the target, as in oral cavity tumours. In case of uncertainties as to the localization of involved nodes, or if the nodes are not identified on a pre-operative scanning, the entire involved level is included.

**CTV3:** The remaining surgical bed and elective nodal areas.

Note: If the indication for radiotherapy is in the T-site alone, no elective nodal irradiation should be performed in pT1 or pT2 tumours.

Tumours confined to the tonsillar fossa and tonsillar pillars are considered lateral tumours and should be treated with ipsilateral radiotherapy. Tumours arising in, or extending to, the base of tongue, soft palate or posterior pharyngeal wall are considered midline tumours and should be treated with bilateral elective irradiation. In pT1-2 with ipsilateral nodal metastasis and contralateral neck dissection with  $\geq 10$  nodes removed without any metastasis, contralateral elective nodal irradiation should be omitted.

#### Elective nodal areas

- pN0: Bilateral level II, III. Retropharyngeal nodes are included in case of posterior wall invasion, and level Ib is included in case of oral cavity involvement. Ib may be included ipsilaterally only, in selected cases
- N1-3: Level II, III. Level IV on the side of nodal involvement. Elective regions are extended at least 2 cm cranially and caudally of GTV-N. If extension to nearby muscle involvement is suspected the entire muscle is included at least 2 cm above and below GTV-N. The retropharyngeal nodes are included in case of posterior pharyngeal wall involvement and level Ib is included in case of oral cavity involvement. Ib may be included ipsilaterally only, in selected cases.

## Hypopharynx

**Anatomy:** Hypopharynx is limited by oropharynx, larynx, and oesophagus. *The anterior wall* includes arytenoid cartilage and aryepiglottic fold to the lower cricoid cartilage. *Pyriform sinus* includes pharyngo-epiglottic fold and the upper extension of oesophagus, laterally to the thyroid cartilage and medially from the hypopharyngeal surface of the aryepiglottic fold, arytenoid cartilage, and cricoid cartilage. The hypo-pharyngeal posterior wall extends from a level through the hyoid bone (bottom of vallecula) to the lower border of the cricoid cartilage and from apex of one pyriform sinus to the other.

**CTV1:** Primary tumour (GTV-T) and involved lymph nodes (GTV-N) with an isotropic margin of 5 mm. Larger margins should be used for ill-defined tumours and margins should be cropped for air and natural barriers such as bone, unless bone involvement is evident.

**CTV2:** GTV-T and -N with an isotropic margin of 10 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers such as bone. In case of T1/T2 primaries, the prevertebral fascia and the thyroid cartilage can be considered as a natural barrier.

**CTV3:** Elective nodal regions are:

- N0: bilateral level II, III and IV. The cranial part of level II can be excluded after individual consideration on the uninvolved side(s).
- N1-3: bilateral level II, III and IV. Elective regions are extended at least 2 cm cranially and caudally of GTV-N. If extension to nearby muscle involvement is suspected the entire muscle is included at least

2 cm above and below GTV-N. In case of subglottic or oesophageal involvement level VIa+b is included.

## Supraglottic larynx

*Anatomy:* Supraglottic larynx includes larynx above the vocal folds i.e. the suprahoid part of epiglottis (lingual and laryngeal surface above hyoid bone), aryepiglottic folds, infrahyoid epiglottis, ventricular folds, and sinus of Morgagni.

**CTV1:** Primary tumour (GTV-T) and involved lymph nodes (GTV-N) with an isotropic margin of 5 mm. Larger margins should be used for ill-defined tumours and margins should be cropped for air and natural barriers such as bone, unless bone involvement is evident.

**CTV2:** GTV-T and -N with an isotropic margin of 10 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers such as bone. For T1 tumours the thyroid cartilage and prelaryngeal muscle is considered a natural barrier. For T2 tumours the pre-laryngeal muscles are considered as a natural barrier.

**CTV3:** Elective nodal regions:

- N0: bilaterally level II and III.
- N1-3: bilaterally level II and III. Level IV on the side of nodal involvement or bilateral in case of hypopharyngeal involvement. Elective regions are ex-tended at least 2 cm cranially and caudally of GTV-N. If extension to nearby muscle involvement is suspected the entire muscle is included at least 2 cm above and below GTV-N
- In case of subglottic or oesophageal involvement, level VIa+b is added
- The stoma is included in case of tracheostomy. The stoma is defined as the incision + 5mm

## Glottic larynx

*Anatomy:* The region includes vocal cords, anterior and posterior commissure

*For T1N0*

**CTV1:** Includes primary tumour (GTV-T) with an isotropic margin of 5 mm. Larger margins should be used for ill-defined tumours and margins should be cropped for air and natural barriers. The thyroid cartilage is considered a natural barrier. There is no CTV2.

*For T2N0:*

**CTV1:** Includes primary tumour (GTV-T) with an isotropic margin of 5 mm. Larger margins should be used for ill-defined tumours and margins should be cropped for air and natural barriers. The thyroid cartilage is considered a natural barrier.

**CTV2:** GTV-T and -N with an isotropic margin of 10 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers. CTV2 can be individually expanded to include high risk areas. CTV2 could be left out in case of superficial tumours without involvement of the anterior commissure.

**CTV3:**

- As a rule, no elective irradiation is used.
- Nodal irradiation could be considered in non-superficial T2N0. Elective areas are dependent on areas of involvement. Often level III and caudal level II
- In case of supraglottic extension, elective nodes should be irradiated according to recommendations for that site
- In case of subglottic or oesophageal involvement, level VIa+b is added
- The stoma is included in case of tracheostomy. The stoma is defined as the incision + 5mm

**T3-4N0 and all N+:**

**CTV1:** Primary tumour (GTV-T) and involved lymph nodes (GTV-N) with an isotropic margin of 5 mm. Larger margins should be used for ill-defined tumours and margins should be cropped for air and natural barriers such as bone, unless bone involvement is evident. Mucosa inside the thyroid cartilage should be included.

**CTV2:** GTV-T and -N with an isotropic margin of 10 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers such as bone. CTV2 can be individually expanded to include high risk areas, e.g. supra- or subglottic larynx.

**CTV3:** Elective nodal regions

- N0: bilaterally level II and III.
- N1-3: bilaterally level II and III. Level IV on the side of nodal involvement, or bilateral in case of hypopharyngeal involvement. Elective regions are extended at least 2 cm cranially and caudally of GTV-N. If extension to nearby muscle involvement is suspected the entire muscle is included at least 2 cm above and below GTV-N
- In case of subglottic or oesophageal involvement, level VIa+b is added
- The stoma is included in case of tracheostomy. The stoma is defined as the incision + 5mm

## Subglottic larynx

*Anatomy:* The region includes larynx below vocal cords.

**CTV1:** Primary tumour (GTV-T) and involved lymph nodes (GTV-N) with an isotropic margin of 5 mm. Larger margins should be used for ill-defined tumours and margins should be cropped for air and natural barriers such as bone, unless bone involvement is evident.

**CTV2:** GTV-T and -N with an isotropic margin of 10 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers such as bone. CTV2 can be individually expanded to include high risk areas, e.g. glottic or supraglottic larynx.

**CTV3:** Elective nodal regions

- N0: bilateral level III, IV, VI, and level II in case of supraglottic extension
- N1-3: bilateral level III, IV, VIa+b, and level II in case of supraglottic extension. Elective regions are extended at least 2 cm cranially and caudally of GTV-N. If extension to nearby muscle involvement is suspected, the entire muscle is included at least 2 cm above and below GTV-N.
- The stoma is included in case of tracheostomy. The stoma is defined as the incision + 5mm

### **Postoperative radiotherapy after primary laryngectomy**

Elective nodal treatment can be performed using (chemo)irradiation or surgery in case of primary total laryngectomy. The target is individually defined by the multidisciplinary team.

**CTV1:** Macroscopic tumour (R2), microscopically non-radical operated areas (R1) or areas of ENE, with an isotropic margin of 5 mm. Larger margins should be used for ill-defined tumours and margins should be cropped for air and natural barriers such as bone, unless bone involvement is evident.

**CTV2:** CTV1 with an isotropic margin of 5 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers such as bone. CTV2 can be individually expanded to include high risk areas.

In case of an absent CTV1, i.e. after radical (R0) surgery, CTV2 includes the pre-operative GTV with at least 10 mm margin. In case of uncertainties as to the localization of involved nodes, or if the nodes are not identified on a pre-operative scanning, the entire involved level is included.

**CTV3:** Includes the remaining surgical bed and potentially elective areas. As a rule, elective nodal areas without additional margin and the tracheostoma with a 5 mm margin is included. Nodal areas as mentioned above for the individual sub-sites.

## **Sinonasal tumours**

**Anatomy:** The region includes nasal cavity posteriorly to the vestibule, the maxillary sinus, ethmoid sinuses, sphenoid sinus, and frontal sinus. All areas are bordered by bone except the anterior and posterior extent of the nasal cavity.

Treatment is decided according to national guidelines (dahanca.dk). The mainstay of treatment is surgery in all operable patients with a R0 resections as the goal. Postoperative radiotherapy is indicated in pT3-pT4 tumours even after radical surgery (R0), in case of R1 or R2 resection and in all cases of uncertainty as to the sufficiency of the margins. Furthermore, postoperative radiotherapy can be considered in pT2. Often, target coverage and normal tissue sparing must be prioritized, based on a case-specific evaluation.

### Primary radiotherapy

**CTV1:** Primary tumour (GTV-T) and involved lymph nodes (GTV-N) with an isotropic margin of 5 mm. Larger margins should be used for ill-defined tumours and margins should be cropped for air and natural barriers such as bone, unless bone involvement is evident.

**CTV2:** GTV-T and -N with an isotropic margin of 10 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers such as bone. Furthermore, the entire involved sinus(es) or ipsilateral nasal cavity is included, as well as other high-risk areas after individual consideration.

**CTV3:** The elective nodal areas are:

- N0: Elective nodal irradiation is considered only in case of involvement of skin, oral cavity, or pharynx. In that case, level Ib and II are included. Level III can be included. Level IV, V, VIIa (retropharyngeal), and VIIb (retrostyloid) are included in case of nasopharyngeal invasion. Ipsilateral radiotherapy can be used in case of limited involvement of e.g. gingiva, without involvement of midline structures. Elective treatment of the neck (surgery or radiotherapy) can be considered in case of T3-T4 tumours, especially in case of squamous cell tumours of the maxillary sinus.
- N1-3: Involved elective regions including the volumes mentioned above. Elective regions are extended at least 2 cm cranially and caudally of GTV-N. If extension to nearby muscle involvement is suspected, the entire muscle is included at least 2 cm above and below GTV-N. Ipsilateral radiotherapy can be used in case of limited involvement, e.g. gingiva, without involvement of midline structures.

### Postoperative radiotherapy

**CTV1:** Includes non-radically operated areas (R2 and R1) with a 5 mm isotropic margin. Margins could individually be enlarged to include high-risk regions and cropped for air and at natural barriers such as bone.

**CTV2:** Includes CTV1 with an isotropic margin of 5 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers such as bone. Should also include the entire involved region, i.e. the involved sinus(es) and/or ipsilateral nasal cavity.

In case of an absent CTV1, i.e. after radical surgery (R0), CTV2 includes the pre-operative GTV plus at least 10 mm and the entire region i.e., the entire involved sinus(es) and/ or nasal cavity.

In case of uncertainties as to the localization of involved nodes, or if the nodes are not identified on a pre-operative scanning, the entire involved level is included.

**CTV3:** Surgical bed plus elective nodal areas.

- N0: Elective treatment is given only in case of involvement of skin, oral cavity, or pharynx. In that case, level Ib and II are included. Level III can be included. Level IV, V, VIIa (retropharyngeal) and VIIb (retrostyloid) are included in case of nasopharyngeal invasion. Ipsilateral radiotherapy can be used in case of limited involvement of e.g. gingiva, without involvement of midline structures. Elective treatment of the neck (surgery or radiotherapy) can be considered in case of T3-T4 tumours, especially in case of squamous cellular tumours of the maxillary sinus.
- N1-3: In case of pN1 without ENE, no elective irradiation is recommended after neck dissection. In case of pN2-pN3, postoperative radiotherapy is recommended irrespective of the result of the neck dissection. T-site irradiation is considered relative to the possibility of irradiating any local-recurrence. CTV3 includes elective regions mentioned above. Elective regions are extended at least 2 cm cranially and caudally of GTV-N. If extension to nearby muscle involvement is suspected the entire muscle is included at least 2 cm above and below GTV-N -N. Ipsilateral radiotherapy can be used in case of limited involvement of e.g. gingiva, without involvement of midline structures.

## Salivary gland

*Anatomy:* Salivary gland tumours arise in the macroscopic glands (parotid, submandibular, and sublingual glands) as well as the entire mucous membranes of the head and neck, predominantly in the oral cavity.

DAHANCA has divided salivary gland tumours into prognostic groups based on histology. The treatment principles are determined by national guidelines ([www.dahanca.dk](http://www.dahanca.dk)). As a rule, surgery is performed as the primary treatment of all operable tumours. Postoperative radiotherapy is recommended after non-radical surgery of the T site (R1 or R2), T $\geq$ T3, N+, perineural invasion, recurrences, and high-grade tumours, irrespective of other risk factors.

DAHANCA has divided salivary gland tumours into prognostic groups based on histology:

*Low grade:* Acinic cell carcinoma, polymorphous low-grade adenocarcinoma, basal cell adenocarcinoma, epithelial-myoepithelial carcinoma, high and intermediate grade mucoepidermoid carcinoma, well-differentiated adenocarcinoma NOS (Not Otherwise Specified), well-differentiated non-invasive or minimally invasive carcinoma of pleomorphic adenoma, clear cell carcinoma NOS, sialoblastoma.

*High grade:* Adenoid cystic carcinoma, intermediate and poorly differentiated adenocarcinoma NOS, intermediate and poorly differentiated carcinoma in pleomorphic adenoma with invasive depth of >1,5 mm, poorly differentiated mucoepidermoid carcinoma, salivary duct carcinoma, primary squamous cell carcinomas, undifferentiated carcinoma (lymphoepithelial carcinoma), large cell carcinoma, mucinous adenocarcinoma, oncocytic carcinoma, carcino-sarcomas, small cell carcinoma, myoepithelial carcinoma.

Perineural invasion (PNI) is a histopathological description and a potential risk factor of loco-regional recurrence and distant metastasis. Perineural spread (PNS) is a clinical /macroscopic concept that describes

growth along macroscopic nerves. It is often asymptomatic and observed per-operatively or on MRI scans. PNI does not imply PNS. PNI is an indication for postoperative radiotherapy. PNS is an indication to expand the CTV along macroscopic nerves. See e.g.(77) for delineation guidelines.

### **Radical radiotherapy:**

**CTV1:** Includes the primary tumour (GTV-T) with a 5 mm isotropic margin plus the entire involved salivary gland. Larger margins should be used for ill-defined tumours and margins should be cropped for air and natural barriers such as bone, unless bone involvement is evident.

**CTV2:** GTV-T and -N with an isotropic margin of 10 mm. cropped for air and at natural barriers such as bone.

**CTV3:** As a rule, elective ipsilateral regions are irradiated only. In case of involvement of midline structures both sides of the neck are irradiated

- Parotid: level II + III + VIII (parotid group)
- Submandibular: level Ia + Ib + II + III
- For all other glands, the principles for the specific region (often oral cavity) is applied. Elective regions are extended at least 2 cm cranially and caudally of any GTV-N. If extension to nearby muscle involvement is suspected, the entire muscle is included at least 2 cm above and below GTV-N.
- In case of PNS along the major branches of the cranial nerves, these are irradiated to the base of skull.

### **Postoperative radiotherapy**

**CTV1:** Macroscopic tumour (R2), microscopically non-radical operated areas (R1) or areas of ECE, with an isotropic margin of 5 mm. Larger margins should be used for ill-defined tumours and margins should be cropped for air and natural barriers such as bone, unless bone involvement is evident

**CTV2:** CTV1 with an isotropic margin of 5 mm. Margins could individually be enlarged to include high risk regions and cropped for air and at natural barriers such as bone.

If no CTV1 is present in case of radical surgery (R0), CTV2 is the pre-operative GTV with an isotropic margin of 10 mm.

Furthermore, the entire salivary gland should always be included in the CTV2.

In case of uncertainties as to the localization of involved nodes, or if the nodes are not identified on a pre-operative scanning, the entire involved level is included.

**CTV3:** Includes the surgical bed and elective areas.

- In case of PNS along the main branches of the cranial nerves, these are irradiated to the base of skull.
- pN0: No elective nodal irradiation is performed.
- N+: As a rule, selective ipsilateral regions are irradiated only. In case of involvement of midline structures both sides of the neck are irradiated

- Parotid: level II + III
- Submandibular: level Ia+ Ib + II + III
- For all other glands the principles for the relevant region (often oral cavity) is applied. Elective regions are extended at least 2 cm cranially and caudally of any GTV-N. If extension to nearby muscle involvement is suspected the entire muscle is included at least 2 cm above and below GTV-N.

## Lymph node metastasis from unknown primary tumour (UP)

*Anatomy:* Neck metastasis from an unknown primary tumour is defined as an undiagnosed primary tumour after thorough diagnostic procedures, at the beginning of treatment.

Diagnostic procedures and treatment follow national guidelines (dahanca.dk).

A distinction is made between squamous cell carcinomas and other histologies.

Neck nodes containing squamous cell carcinoma will often originate from the mucous membranes of the head and neck area. For other histologies, multiple origins may exist. Some can be treated with curative intent, e.g. germ cell tumours, small cell lung cancer, and some are relatively treatment resistant such as melanomas.

### *Radiotherapy for squamous cellular carcinomas*

In case of nodal metastasis from a squamous cellular carcinoma there is, as a rule, indication for treatment of regional lymph nodes as well as potential primary tumour sites. This is *not* the case for other histologies. Irradiation of the ipsilateral neck is difficult without irradiation of contralateral regions which makes irradiation of recurrences difficult. Bilateral irradiation is therefore recommended.

**CTV1:** Includes known macroscopic tumour (non-operated or R2), insufficiently operated areas (R1) or areas of ENE. CTV1 includes involved nodes with an isotropic margin of 5 mm in all direction, cropped for air and at natural barriers such as bone.

**CTV2:** GTV-T and -N with an isotropic margin of 10 mm. Margins could individually be enlarged to include high risk regions, such as mucosal areas with an increased risk of harbouring a primary and cropped for air and at natural barriers such as bone.

**CTV3:** The entire mucous membrane of 5 mm depth, in the pharynx and larynx, from the base of skull to below the cricoid cartilage, including tonsillar fossa on both sides. Base of tongue should be included with a 10 mm margin due to its irregular surface. Elective regions include bilateral level II, III, IV. Level V is included if a nasopharyngeal primary is suspected. Elective regions are extended at least 2 cm cranially and caudally of any GTV-N. If extension to nearby muscle involvement is suspected the entire muscle is included at least 2 cm above and below GTV-N.

*Radiotherapy for non-squamous cell histologies*

In case of adenocarcinoma, treatment depends on the likely localisation of a primary. Localisations include salivary and thyroid glands, nasal cavity and paranasal sinuses, lung, breast, gastro-intestinal canal, uterus, ovary, and prostate. Localisation, immuno-histochemistry, serology and iodine scintigraphy may aid in the search of a primary and guide the treatment. In case of unknown primary after relevant diagnostics, involved field irradiation to curative doses may be indicated, but elective nodal or mucosal irradiation is not recommended.

## 4. References

1. Zukauskaitė R, Hansen CR, Grau C, Samsøe E, Johansen J, Petersen JBB, et al. Local recurrences after curative IMRT for HNSCC: Effect of different GTV to high-dose CTV margins. *Radiother Oncol*. 2018;126(1):48-55.
2. Zukauskaitė R, Hansen CR, Brink C, Johansen J, Asmussen JT, Grau C, et al. Analysis of CT-verified loco-regional recurrences after definitive IMRT for HNSCC using site of origin estimation methods. *Acta Oncol*. 2017;56(11):1554-61.
3. Hansen CR, Johansen J, Kristensen CA, Smulders B, Andersen LJ, Samsøe E, et al. Quality assurance of radiation therapy for head and neck cancer patients treated in DAHANCA 10 randomized trial. *Acta Oncol*. 2015;54(9):1669-73.
4. Lee AW, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. *Radiother Oncol*. 2018;126(1):25-36.
5. Gregoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. *Radiother Oncol*. 2018;126(1):3-24.
6. Xu Y, Zhang Y, Xu Z, Liu S, Xu G, Gao L, et al. Patterns of Cervical Lymph Node Metastasis in Locally Advanced Supraglottic Squamous Cell Carcinoma: Implications for Neck CTV Delineation. *Front Oncol*. 2020;10:1596.
7. Bauwens L, Baltres A, Fiani DJ, Zrounba P, Buiret G, Fleury B, et al. Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma. *Radiother Oncol*. 2021;157:122-9.
8. Chisholm EJ, Elmiyeh B, Dwivedi RC, Fisher C, Thway K, Kerawala C, et al. Anatomic distribution of cervical lymph node spread in parotid carcinoma. *Head Neck*. 2011;33(4):513-5.
9. Stodulski D, Mikaszewski B, Majewska H, Wisniewski P, Stankiewicz C. Probability and pattern of occult cervical lymph node metastases in primary parotid carcinoma. *Eur Arch Otorhinolaryngol*. 2017;274(3):1659-64.
10. Terzidis E, Friborg J, Vogelius IR, Lelkaitis G, von Buchwald C, Olin AB, et al. Tumor volume definitions in head and neck squamous cell carcinoma - Comparing PET/MRI and histopathology. *Radiother Oncol*. 2023;180:109484.
11. Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reyckers H, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. *Radiology*. 2004;233(1):93-100.

12. Smits HJG, Raaijmakers CPJ, de Ridder M, Gouw ZAR, Doornaert PAH, Pameijer FA, et al. Improved delineation with diffusion weighted imaging for laryngeal and hypopharyngeal tumors validated with pathology. *Radiother Oncol.* 2024;194:110182.
13. Ligtenberg H, Jager EA, Caldas-Magalhaes J, Schakel T, Pameijer FA, Kasperts N, et al. Modality-specific target definition for laryngeal and hypopharyngeal cancer on FDG-PET, CT and MRI. *Radiother Oncol.* 2017;123(1):63-70.
14. Hansen CR, Johansen J, Samsoe E, Andersen E, Petersen JBB, Jensen K, et al. Consequences of introducing geometric GTV to CTV margin expansion in DAHANCA contouring guidelines for head and neck radiotherapy. *Radiother Oncol.* 2018;126(1):43-7.
15. Due AK, Vogelius IR, Aznar MC, Bentzen SM, Berthelsen AK, Korreman SS, et al. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. *Radiother Oncol.* 2014;111(3):360-5.
16. Raktoe SA, Dehnad H, Raaijmakers CP, Braunius W, Terhaard CH. Origin of tumor recurrence after intensity modulated radiation therapy for oropharyngeal squamous cell carcinoma. *Int J Radiat Oncol Biol Phys.* 2013;85(1):136-41.
17. Ferreira BC, Marques RV, Khouri L, Santos T, Sa-Couto P, do Carmo Lopes M. Assessment and topographic characterization of locoregional recurrences in head and neck tumours. *Radiat Oncol.* 2015;10:41.
18. Ou X, Yan W, Huang Y, He X, Ying H, Lu X, et al. Unraveling the patterns and pathways of local recurrence of nasopharyngeal carcinoma: evidence for individualized clinical target volume delineation. *Radiat Oncol.* 2023;18(1):55.
19. Wang L, Huang S, Zhang L, He X, Liu Y. Recommendation regarding the cranial upper border of level IIb in delineating clinical target volumes (CTV) for nasopharyngeal carcinoma. *Radiat Oncol.* 2020;15(1):270.
20. Wu Z, Qi B, Lin FF, Zhang L, He Q, Li FP, et al. Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation. *Radiother Oncol.* 2023;183:109595.
21. Navran A, Heemsbergen W, Janssen T, Hamming-Vrieze O, Jonker M, Zuur C, et al. The impact of margin reduction on outcome and toxicity in head and neck cancer patients treated with image-guided volumetric modulated arc therapy (VMAT). *Radiother Oncol.* 2019;130:25-31.
22. Hansen CR, Christiansen RL, Lorenzen EL, Bertelsen AS, Asmussen JT, Gyldenkerne N, et al. Contouring and dose calculation in head and neck cancer radiotherapy after reduction of metal artifacts in CT images. *Acta Oncol.* 2017;56(6):874-8.
23. van Mourik AM, Sonke JJ, Vijlbrief T, Dewit L, Damen EM, Remeijer P, et al. Reproducibility of the MRI-defined spinal cord position in stereotactic radiotherapy for spinal oligometastases. *Radiother Oncol.* 2014;113(2):230-4.
24. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. *Eur J Nucl Med Mol Imaging.* 2015;42(2):328-54.
25. Braunstein S, Glastonbury CM, Chen J, Quivey JM, Yom SS. Impact of Neuroradiology-Based Peer Review on Head and Neck Radiotherapy Target Delineation. *AJNR Am J Neuroradiol.* 2017;38(1):146-53.
26. Adjogatse D, Petkar I, Reis Ferreira M, Kong A, Lei M, Thomas C, et al. The Impact of Interactive MRI-Based Radiologist Review on Radiotherapy Target Volume Delineation in Head and Neck Cancer. *AJNR Am J Neuroradiol.* 2023;44(2):192-8.

27. Gatfield ER, Benson RJ, Jadon R, Das T, Barnett GC. The impact of neuroradiology collaboration in head and neck cancer radiotherapy peer review. *Br J Radiol*. 2022;96(1143):20210238.
28. de Bondt RB, Nelemans PJ, Hofman PA, Casselman JW, Kremer B, van Engelshoven JM, et al. Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging. *Eur J Radiol*. 2007;64(2):266-72.
29. de Bondt RB, Nelemans PJ, Bakers F, Casselman JW, Peutz-Kootstra C, Kremer B, et al. Morphological MRI criteria improve the detection of lymph node metastases in head and neck squamous cell carcinoma: multivariate logistic regression analysis of MRI features of cervical lymph nodes. *Eur Radiol*. 2009;19(3):626-33.
30. van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, et al. Cervical lymph node metastasis: assessment of radiologic criteria. *Radiology*. 1990;177(2):379-84.
31. Evans M, Beasley M. Target delineation for postoperative treatment of head and neck cancer. *Oral Oncol*. 2018;86:288-95.
32. Bittermann G, Wiedenmann N, Bunea A, Schwarz SJ, Grosu AL, Schmelzeisen R, et al. Clipping of tumour resection margins allows accurate target volume delineation in head and neck cancer adjuvant radiation therapy. *Radiother Oncol*. 2015;116(1):82-6.
33. Gregoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. *Radiother Oncol*. 2014;110(1):172-81.
34. Gerard M, Le Guevelou J, Jacksic N, Lequesne J, Bastit V, Gery B, et al. Postoperative radiotherapy after flap reconstructive surgery in patients with head and neck cancer: A retrospective monocentric study with flap delineation to assess toxicity and relapse. *Cancer Radiother*. 2020;24(8):851-9.
35. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. *N Engl J Med*. 2019;381(12):1124-35.
36. Salama JK, Haddad RI, Kies MS, Busse PM, Dong L, Brizel DM, et al. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. *Int J Radiat Oncol Biol Phys*. 2009;75(3):725-33.
37. Yang H, Chen X, Lin S, Rong J, Yang M, Wen Q, et al. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. *Radiother Oncol*. 2018;126(1):37-42.
38. Xiang L, Rong JF, Xin C, Li XY, Zheng Y, Ren PR, et al. Reducing Target Volumes of Intensity Modulated Radiation Therapy After Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial. *Int J Radiat Oncol Biol Phys*. 2023;117(4):914-24.
39. Santanam L, Hurkmans C, Mutic S, van Vliet-Vroegindeweij C, Brame S, Straube W, et al. Standardizing naming conventions in radiation oncology. *Int J Radiat Oncol Biol Phys*. 2012;83(4):1344-9.
40. Mayo C, Yorke E, Merchant TE. Radiation associated brainstem injury. *Int J Radiat Oncol Biol Phys*. 2010;76(3 Suppl):S36-41.
41. Weber DC, Rutz HP, Pedroni ES, Bolsi A, Timmermann B, Verwey J, et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. *Int J Radiat Oncol Biol Phys*. 2005;63(2):401-9.
42. Debus J, Hug EB, Liebsch NJ, O'Farrel D, Finkelstein D, Efird J, et al. Brainstem tolerance to conformal radiotherapy of skull base tumors. *Int J Radiat Oncol Biol Phys*. 1997;39(5):967-75.

43. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. *Int J Radiat Oncol Biol Phys*. 2010;76(3 Suppl):S42-9.
44. Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J. Radiation dose-volume effects of optic nerves and chiasm. *Int J Radiat Oncol Biol Phys*. 2010;76(3 Suppl):S28-35.
45. Jeganathan VS, Wirth A, MacManus MP. Ocular risks from orbital and periorbital radiation therapy: a critical review. *Int J Radiat Oncol Biol Phys*. 2011;79(3):650-9.
46. Su SF, Huang Y, Xiao WW, Huang SM, Han F, Xie CM, et al. Clinical and dosimetric characteristics of temporal lobe injury following intensity modulated radiotherapy of nasopharyngeal carcinoma. *Radiother Oncol*. 2012;104(3):312-6.
47. Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE, et al. Radiation dose-volume effects in the brain. *Int J Radiat Oncol Biol Phys*. 2010;76(3 Suppl):S20-7.
48. Bhandare N, Jackson A, Eisbruch A, Pan CC, Flickinger JC, Antonelli P, et al. Radiation therapy and hearing loss. *Int J Radiat Oncol Biol Phys*. 2010;76(3 Suppl):S50-7.
49. Chan SH, Ng WT, Kam KL, Lee MC, Choi CW, Yau TK, et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. *Int J Radiat Oncol Biol Phys*. 2009;73(5):1335-42.
50. Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. *Int J Radiat Oncol Biol Phys*. 2009;73(3):779-88.
51. Bath SS, Caudell JJ, Chen AM. Practical considerations in reducing swallowing dysfunction following concurrent chemoradiotherapy with intensity-modulated radiotherapy for head and neck cancer. *Head Neck*. 2014;36(2):291-8.
52. Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). *Int J Radiat Oncol Biol Phys*. 2010;76(5):1333-8.
53. Aarup-Kristensen S, Hansen CR, Forner L, Brink C, Eriksen JG, Johansen J. Osteoradionecrosis of the mandible after radiotherapy for head and neck cancer: risk factors and dose-volume correlations. *Acta Oncol*. 2019;58(10):1373-7.
54. van Dijk LV, Abusaif AA, Rigert J, Naser MA, Hutcheson KA, Lai SY, et al. Normal Tissue Complication Probability (NTCP) Prediction Model for Osteoradionecrosis of the Mandible in Patients With Head and Neck Cancer After Radiation Therapy: Large-Scale Observational Cohort. *Int J Radiat Oncol Biol Phys*. 2021;111(2):549-58.
55. Hawkins PG, Lee JY, Mao Y, Li P, Green M, Worden FP, et al. Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life. *Radiother Oncol*. 2018;126(1):68-74.
56. Dean JA, Wong KH, Welsh LC, Jones AB, Schick U, Newbold KL, et al. Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy. *Radiother Oncol*. 2016;120(1):21-7.
57. Hansen CR, Bertelsen A, Zukauskaitė R, Johnsen L, Bernchou U, Thwaites DI, et al. Prediction of radiation-induced mucositis of H&N cancer patients based on a large patient cohort. *Radiother Oncol*. 2020;147:15-21.
58. Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. *Int J Radiat Oncol Biol Phys*. 2010;76(3 Suppl):S58-63.
59. Darzy KH, Shalet SM. Hypopituitarism following radiotherapy. *Pituitary*. 2009;12(1):40-50.
60. Paulissen MJ, Zegers CML, Houben RM, Hofstede D, Kars M, van Santen HM, et al. Radiotherapy-induced Hypothalamic-Pituitary axis dysfunction in adult Brain, head and neck and skull base tumor patients - A systematic review and Meta-Analysis. *Clin Transl Radiat Oncol*. 2025;51:100900.

61. Ronjom MF, Brink C, Bentzen SM, Hegedus L, Overgaard J, Johansen J. Hypothyroidism after primary radiotherapy for head and neck squamous cell carcinoma: normal tissue complication probability modeling with latent time correction. *Radiother Oncol.* 2013;109(2):317-22.
62. Boomsma MJ, Bijl HP, Langendijk JA. Radiation-induced hypothyroidism in head and neck cancer patients: a systematic review. *Radiother Oncol.* 2011;99(1):1-5.
63. Choi HS, Jeong BK, Jeong H, Song JH, Kim JP, Park JJ, et al. Carotid sparing intensity modulated radiotherapy on early glottic cancer: preliminary study. *Radiat Oncol J.* 2016;34(1):26-33.
64. Gondi V, Hermann BP, Mehta MP, Tome WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. *Int J Radiat Oncol Biol Phys.* 2013;85(2):348-54.
65. Nieder C, Grosu AL, Andratschke NH, Molls M. Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients. *Int J Radiat Oncol Biol Phys.* 2005;61(3):851-5.
66. Embring A, Onjukka E, Mercke C, Lax I, Berglund A, Bornedal S, et al. Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects. *Cancers (Basel).* 2021;13(13).
67. Nix M, Gregory S, Aldred M, Aspin L, Lilley J, Al-Qaisieh B, et al. Dose summation and image registration strategies for radiobiologically and anatomically corrected dose accumulation in pelvic re-irradiation. *Acta Oncol.* 2022;61(1):64-72.
68. Bahhous K, Zerfaoui M, Rahmouni A, El Khayati N. Enhancing benefits of bolus use through minimising the effect of air-gaps on dose distribution in photon beam radiotherapy. *Journal of Radiotherapy in Practice.* 2021;20(2):210-6.
69. Sharma MB, Jensen K, Friberg J, Smulders B, Andersen E, Samsoe E, et al. Target coverage and local recurrences after radiotherapy for sinonasal cancer in Denmark 2008-2015. A DAHANCA study. *Acta Oncol.* 2022;61(2):120-6.
70. Yao CY, Zhou GR, Wang LJ, Xu JH, Ye JJ, Zhang LF, et al. A retrospective dosimetry study of intensity-modulated radiotherapy for nasopharyngeal carcinoma: radiation-induced brainstem injury and dose-volume analysis. *Radiat Oncol.* 2018;13(1):194.
71. Leblond P. SIOP-Ependymoma-II-Protocol-v3.1-22-April-2020. 2020.
72. Stieb S, Snider JW, 3rd, Placidi L, Kliebsch U, Lomax AJ, Schneider RA, et al. Long-Term Clinical Safety of High-Dose Proton Radiation Therapy Delivered With Pencil Beam Scanning Technique for Extracranial Chordomas and Chondrosarcomas in Adult Patients: Clinical Evidence of Spinal Cord Tolerance. *Int J Radiat Oncol Biol Phys.* 2018;100(1):218-25.
73. Fung V, Calugaru V, Bolle S, Mammar H, Alapetite C, Maingon P, et al. Proton beam therapy for skull base chordomas in 106 patients: A dose adaptive radiation protocol. *Radiother Oncol.* 2018;128(2):198-202.
74. van Herk M. Errors and margins in radiotherapy. *Semin Radiat Oncol.* 2004;14(1):52-64.
75. Dale RG, Hendry JH, Jones B, Robertson AG, Deehan C, Sinclair JA. Practical methods for compensating for missed treatment days in radiotherapy, with particular reference to head and neck schedules. *Clin Oncol (R Coll Radiol).* 2002;14(5):382-93.
76. Ng WT, Chan SH, Lee AW, Lau KY, Yau TK, Hung WM, et al. Parapharyngeal extension of nasopharyngeal carcinoma: still a significant factor in era of modern radiotherapy? *Int J Radiat Oncol Biol Phys.* 2008;72(4):1082-9.
77. Biau J, Dunet V, Lapeyre M, Simon C, Ozsahin M, Gregoire V, et al. Practical clinical guidelines for contouring the trigeminal nerve (V) and its branches in head and neck cancers. *Radiother Oncol.* 2019;131:192-201.

78. Brouwer CL, Steenbakkers RJ, Bourhis J, Budach W, Grau C, Gregoire V, et al. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. *Radiother Oncol*. 2015;117(1):83-90.
79. Christianen ME, Langendijk JA, Westerlaan HE, van de Water TA, Bijl HP. Delineation of organs at risk involved in swallowing for radiotherapy treatment planning. *Radiother Oncol*. 2011;101(3):394-402.
80. Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS, et al. Hippocampal-sparing whole-brain radiotherapy: a "how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys*. 2010;78(4):1244-52.
81. Nowak PJ, Wijers OB, Lagerwaard FJ, Levendag PC. A three-dimensional CT-based target definition for elective irradiation of the neck. *Int J Radiat Oncol Biol Phys*. 1999;45(1):33-9.
82. Jensen K, Al-Farra G, Dejanovic D, Eriksen JG, Loft A, Hansen CR, et al. Imaging for Target Delineation in Head and Neck Cancer Radiotherapy. *Semin Nucl Med*. 2021;51(1):59-67.
83. Jensen K, Friborg J, Hansen CR, Samsoe E, Johansen J, Andersen M, et al. The Danish Head and Neck Cancer Group (DAHANCA) 2020 radiotherapy guidelines. *Radiother Oncol*. 2020;151:149-51.

## 5. Method

### Literature search

No formalized literature search has been performed.

### Literature review

The evidence level is in general low, but most often international agreement has been reached on the overlying principles of therapy. Some recommendations rely on international guidelines e.g. by the ICRU (International Commission on Radiation Units and Measurements)

### Formulation of the recommendations

All recommendations have been reviewed and discussed among the DAHANCA radiotherapy quality assurance group with physician and physicist representatives from all centres.

### Stakeholder involvement

Patient values and preferences are not relevant in this technical aspect and therefore no attempt has been made for establishing a patient panel.

### Hearing

No formal peer review process has been performed although the Danish Head and Neck Cancer group have formally also approved the guidelines. This multidisciplinary group represents all medical specialties and medical physicists involved in the diagnosis, treatment, and follow up of head and neck cancer patients.

### Approval

#### *Content approval:*

DAHANCA

#### *Administrative approval:*

Is completed by the secretariat before approval.

### Recommendations that entail significant additional costs

No new specific resource-demanding recommendations have been proposed in the present guidelines, although all guidelines add to the increasing complexity of treatment.

### Need for further research

The target margins and normal tissue sparing are the subject for several projects within the DAHANCA group.

### Authors and conflicts of interest

#### **Rigshospitalet, Copenhagen University Hospital**

- *Consultant Mogens Bernsdorf*
- *Medical physicist Bob Smulders*

#### **University Hospital Herlev**

- *Consultant Christian Maare*
- *Medical physicist Patrik Sibolt*

#### **Odense University Hospital**

- *Consultant Jørgen Johansen*
- *Consultant Ruta Zukauskaitė*
- *Medical physicist Christian Rønn Hansen*
- *Medical physicist Anders Bertelsen*

#### **Aalborg University Hospital**

- *Consultant Maria Andersen*
- *Medical physicist Martin Skovmos Nielsen*

#### **Aarhus University Hospital**

- *Professor Jesper Grau Eriksen*
- *Medical physicist Anne Holm*

#### **Sealand University Hospital**

- *Consultant Mohammad Farhadi*
- *Medical physicist Laura Patricia Kaplan*

#### **Danish Centre for Particle Therapy**

- *Professor Cai Grau*
- *Consultant Kenneth Jensen*
- *Medical physicist Peter Sandager Skyt*
- *Medical physicist Ulrik Vindelev Elstrøm*

None of the authors of the guidelines have declared conflicts of interest with regard to any medico-technical companies relevant for the guidelines.

For detailed cooperative relationships, please refer to the declaration via the Danish Medicines Agency's website

#### Plan for revision

The guidelines will be frequently updated as site specific guidelines are approved by DAHANCA and technical development within the field will be closely monitored

#### Version of guideline template

The guideline has been developed in the 3.0 version of the template.

## 6. Monitoring

### Standards and indicators

Development of quality in this area is supported by knowledge from the DAHANCA database) under the auspices of the Danish Healthcare Quality Institute (SundK), as the indicators in the database must illuminate relevant clinical guidelines

The clinical quality database's steering group has the mandate to decide on the database's indicator set, including which specific processes and results are monitored in the database.

If the author group has proposals for specific recommendations that can be usefully included in the steering group's discussion in connection with the ongoing revision of the indicator set, they can be listed here:

*Adherence to the guidelines is monitored for the large number of patients included in clinical protocols. Many overall quality indicators are monitored in the clinical DAHANCA database and included in the yearly report. Furthermore: See chapter on "Quality assurance"*

### Plan for audit and feedback

The guidelines are evaluated at each meeting in the DAHANCA quality assurance group, with meetings two-three times annually. Work has been initiated for the next update.

## 7. Appendices

### Appendix 1: Delineation of organs at risk

Organ	Cranial	Caudal	Anterior	Posterior	Lateral	Medial	Reference delineation*
BrainStem	Bottom of the 3rd ventricle	Tip of the dens of C2					Brouwer(78). Except cranial extended to the bottom of 3rd ventricle.
SpinalCord	Tip of the dens of C2						Brouwer(78)
Chiasm			Optic nerve. ie. chiasma is a Line" not a "H"	Optic tract	A. carotis interna/ cerebri media		
OpticNerve_L OpticNerve_R							
EyeBack_L EyeBack_R (Eye except EyeFront)			EyeFront				
EyeFront_L EyeFront_R (cornea, iris, lens)*			Structures anterior of the vitreous humour				
Lacrimal_L Lacrimal_R  (gl. lacrimalis)	Supralateral to the eye						
Brain	Entire Brain except brainstem						
Cochlea_L Cochlea_R	Hypodense volume in temporal bone anterior to canalis auditoria interna						

Esophagus (cervical esophagus+ esophagus inlet muscle+ cricopharyngeal muscle)	First slice caudal to the arytenoid cartilages	Sternal notch	Posterior edge of cricoid cartilage. tracheal lumen	Prevertebral muscle	Thyroid cartilage, fatty tissue, thyroid gland. Thyroid cartilage		Cervical esophagus+ esophagus inlet muscle+ cricopharyngeal muscle as in Christianen(79)
LarynxG  (glottic larynx)	Upper edge of the arytenoid cartilages	Lower edge of cricoid cartilage (if soft tissue is present)	Thyroid cartilage	Inferior PCM, pharyngeal lumen/ cricoid cartilage	Thyroid cartilage	Pharyngeal lumen (lumen excluded)	Christianen(79)
LarynxSG (supraglottic larynx)	Tip of epiglottis	First slice cranial to the upper edge of the arytenoid cartilages	Hyoid bone, pre-epiglottic space, thyroid cartilage	Pharyngeal lumen, inferior PCM	Thyroid cartilage	Pharyngeal lumen (lumen excluded)	
Mandible	Mandible teeth excluded						
OralCavity (=Brouwer extended oral cavity)	Hard palate mucosa and mucosal reflections near the maxilla	The base of tongue mucosa and hyoid posteriorly and the mylohyoid m. and ant. belly of the digastric m. anteriorly	Inner surface of the mandible and maxilla	Post. borders of soft palate, uvula, and more inferiorly the base of tongue	Inner surface of the mandible and maxilla		Brouwer(78)
Parotid_L Parotid_R							
PCM_Low (lower pharyngeal constrictor)	First slice caudal to the lower edge of hyoid bone	Lower edge of the arytenoid cartilages	Soft tissue of supraglottic/ glottic larynx	Prevertebral muscle	Superior horn of thyroid cartilage		Christianen(79)
PCM_Mid (middle pharyngeal constrictor)	Upper edge of C3	Lower edge of hyoid bone	Base of tongue, hyoid	Prevertebral muscle	Greater horn of hyoid bone	Pharyngeal lumen	
PCM_Up (upper pharyngeal constrictor)	Caudal tip of the pterygoid plates (hamulus)	Lower edge of C2	Hamulus of pterygoid plate; mandibula; base of	Prevertebral muscle	Medial pterygoid muscle	Pharyngeal lumen	

			tongue; pharyngeal lumen				
Pituitary	Gland as seen on MRI or inner part of sella turcica						Brouwer(78)
Submandibular_L Submandibular_R	Med. pterygoid m., mylohyoid m.	Fatty tissue	Lat. Surface mylohyoid m., hyoglossus m.	Parapharyngeal space, sternocleidomastoid m.	Med. surface med. pterygoid m., med. surface mandibular bone, platysma	Lat. surface mylohyoid m., hyoglossus m., superior and middle pharyngeal constrictor m., anterior belly of the digastric m.	
Thyroid							
A_Carotid_L A_Carotid_R							
Buccal mucosa	Bottom of maxillary sinus	Upper edge teeth sockets	Lips, teeth	Med. pterygoid m.	Buccal fat	Outer surface of the mandible and maxilla, oral cavity/base of tongue/soft palate	
Lips	Hard palate (lateral), anterior nasal spine (at the midline)	Lower edge teeth sockets, cranial edge mandibular body	Outer surface of the skin	Mandibular body, teeth, tongue, air (if present)	Depressor anguli oris m. buccinator m. levator anguli oris, m. risorius m. (the mentioned muscles are all lateral to the m. orbicularis oris)	Hard palate (lateral), anterior nasal spine (at the midline)	
Hippocampus	Bilateral structures. Defined by MRI T1-hypointense signal medial to the temporal horn.						Gondi(80) <a href="http://www.rtog.org/CoreLab/ContouringAtlases/HippocampusSparing.aspx">http://www.rtog.org/CoreLab/ContouringAtlases/HippocampusSparing.aspx</a>

## Appendix 2: Applicable dose and fractionation schedules

Using IMRT with simultaneous integrated boost, the following dose and fractionation schedules may be prescribed.

Fractionation schedules DAHANCA 2019	CTV1				CTV2		CTV3	
	Total dose	Dose/fx	fx	Fx/W	Total dose	Dose/fx	Total dose	Dose/fx
Conventional fx	66	2	33	5*	60	1.82	50	1.52
Conventional fx	68	2	34	5*	60	1.76	50	1.47
Accelerated fx	66	2	33	6	60	1.82	50	1.52
Accelerated fx	68	2	34	6	60	1.76	50	1.47
Accelerated hyperfx	76	1.36	56	10	66	1.18	56	1

\*5 fractions per week is used for non-squamous cell carcinoma, postoperative and unknown primaries only

## Appendix 3: DAHANCA – guidelines 2000-2025

The guideline is to a large extent a product of discussion within the DAHANCA Radiotherapy Quality Assurance Group, through an extended period from the very first guidelines in 2000.

DAHANCA, the Danish Head and Neck Cancer Group, was founded in 1976. The group has a long-standing tradition for conducting clinical trials as well as establishing national guidelines for radiotherapy for head and neck cancer. DAHANCA was the first Danish cooperative group to introduce national guidelines for CT-based conformal RT and IMRT.

*The first edition* of the guidelines was implemented in 2000 after it was approved by the DAHANCA group in December 1999. With that, ICRU compatible terminology was implemented at all Danish referral centres for head and neck cancer.

*The second edition* (2002) was approved at the DAHANCA meeting on the 13<sup>th</sup> of December 2001. The following minor adjustments were made:

- The possibility of treating T1a carcinomas of the vocal cord with only 62 Gy was removed.
- The elective target for primaries of the oropharynx was changed from level II-IV to level II, III (+ retro-pharyngeal nodes in case of tumour in the posterior pharyngeal wall, and potentially level IV in case of N2-3).

*The third edition* (2004) was approved at the DAHANCA Radiotherapy Quality Assurance Group meeting 14<sup>th</sup> of September 2004. The following major changes were made:

- CTV-T(tumour) was redefined to "Areas of known macroscopic tumour (GTV), microscopically incompletely resected tumour, or areas of known extra-nodal extension" to comply with post-operative radiotherapy recommendations.

- CTV-E(lective) was divided into CTV-E(high-risk) and CTV-E(low-risk). CTV-high-risk was only relevant for post-operative radiotherapy or IMRT and treated to 60 Gy.
- Elective nodal regions were defined according to the Brussels-Rotterdam consensus, instead of Nowak(81). Tables and figures from the original publication were included as appendices.
- A modification of the inclusion of the upper part of level 2 was allowed for cancers of the larynx and hypopharynx.
- An appendix with guidelines for the use and implementation in IMRT, including fractionation and normal tissue constraints, was included as an appendix.

*The fourth edition (2013)* was approved at the DAHANCA meeting 10<sup>th</sup> of December 2012. All chapters were thoroughly revised in order to comply with the ICRU guidelines and to define important parameters of quality assurance. Furthermore,

- A detailed list of sensitive normal tissues and constraints was added.
- The terms CTV-T, CTV-N, CTV-E(high-risk), CTV-E(low-risk) were renamed into the new terms CTV1, CTV2 and CTV3, and ITV was included into the definition of CTV.
- The margins around GTV were thoroughly discussed. The existing guidelines had been interpreted with large departmental variations. Margins of 0-10 mm from GTV to CTV had been used. The adopted margins were thus a compromise: A 5 + 5 mm margin from GTV to CTV1, and from CTV1 to CTV2, respectively, were suggested.
- A table of minor and major deviations for dose and fractionation for QA, and a table of recommended dose-fractionation schedules were added.

The following minor revisions have been approved May 22<sup>nd</sup> 2014

- A precision that the added margin, GTV to CTV2, should not exceed 12 mm.
- Grégoire (33) added as reference.
- It is emphasized that the spinal cord should always be delineated and that the brain stem should be delineated in case of elective irradiation.
- The constraint of cochlea is corrected to  $D_{5\%} \leq 55\text{Gy}$ .
- All treatment interruptions and prolongations must be compensated. The word “unintended” has been erased.
- Oropharyngeal and supraglottic tumours: Level IV has been excluded in case of N1-3 neck disease and the sentence: “Level IV on the side of nodal involvement” has been inserted in order to avoid level IV irradiation to the non-involved side of the neck.
- Regarding postoperative radiotherapy after laryngectomy: In case of planned primary total laryngectomy, with postoperative (chemo-)radiotherapy, elective nodal areas can be treated with radiotherapy. The treatment plan is made individually by the multidisciplinary team.
- Regarding postoperative radiotherapy for salivary gland tumours: In case of pN0, the elective nodes are not to be irradiated.
- Regarding Unknown primary: The wording has been brought up to date with the “National Guidelines for the Treatment of Lymph Node Metastasis from Unknown Primary”

*Fifth edition (2018)* was approved at the DAHANCA meeting September 19<sup>th</sup>, 2018. All chapters were thoroughly revised, with the following major revisions:

- New chapters and sections on proton therapy and perineural spread.
- Normal tissue delineations according to new international guidelines. Among others, the hippocampus was included as a new organ at risk.
- The guidelines by Lee (4) has inspired a thorough revision of the guidelines regarding nasopharyngeal CTV
- The guidelines by Grégoire (5) inspired a thorough revision of the guidelines for larynx and pharynx cancer.
- The standardized nomenclature for OARs and targets(39) were included and mentioned in an appendix.

*In the sixth edition (2020), a separate chapter has been added on postoperative radiotherapy. The chapter regarding GTV delineation was added and published(82). From, and including the sixth edition, the English version is considered the reference document and the Danish version is the translation. The 2020 Guidelines were published(83).*

In the present 2025 guidelines the following issues are included: Constraints for hypofractionation, planning of reirradiation, target definition after induction chemotherapy, planning of complex target, and clarification of the guidelines for elective targets.

## Appendix 4 Comments to the elective nodal areas of Gregoire

DAHANCA QA Comments to the guidelines and atlas for elective nodal volumes

[Gregoire Radiotherapy and Oncology 110 (2014) 172–181](33)

### General Comments

In patients with “non-average” anatomy or positioning, levels may be modified.

Examples:

Long neck: Level 4 may be shortened more caudal than 2 cm above the manubrium

Short Neck: Level 4 may not be present or very short, and elective areas may be defined more caudally.

"Low" manubrium: As short neck

Hyperextended neck: Transverse process of C1 and hyoid bone may not be ideal landmarks for nodal levels

Severe obesity: Platysma/ skin should not always be used as boundaries, but levels (Ia+b, II) may be shortened in the periphery

Visible lymph nodes, without any signs of malignancy, outside defined levels should not be included

Whenever the SCM is the anterior/ posterior border of a level, the border is defined radially toward the centre of the patient and not a "horizontal" line

### Level 1b

The submandibular gland is a part of level 1b. Level 1b therefore continues caudally to caudal tip of submandibular gland.

**Clarification:** Anterior border of level 1b below hyoid bone (If the caudal edge of the submandibular gland is present below the hyoid bone): To the mid-line.

### Level II

**Note:** The lateral border of level II is m. digastricus venter post. That allows for better parotid sparing!

**Note:** The caudal edge of the lateral process of C1 is the cranial boundary. Any extension will harm parotid sparing

Version 2.0

**Note:** The area between anterior SCM and posterior mandible/ submandibular gland caudal of parotid gland should be included to the platysma.

**Clarification:** Cranially: Level II is defined below the SCM posteriorly, only where a space is visible. SMC becomes an aponeurosis cranially and continues far posteriorly. This varies according to patient positioning.

### Level III

**Correction:** Level III cranially extends anteriorly to the submandibular gland. Caudal of the submandibular gland, the anterior border of SCM defines the level. (In Gregoire: the atlas shows an antero-lateral extension not mentioned in the table)

**Clarification:** Anterior level III between SCM and pre-laryngeal muscles is sometimes not visible. In that case a target is defined anyway, as a 3 mm wide line.

### Level IV (=Level 4a in Gregoire)

**Clarification:** The caudal border is defined as 2 cm above manubrium. In patients with a very long or short neck, this may be modified. Level 4b is included only in order to achieve 2 cm elective irradiation below GTV-N

**Clarification:** Anterior level IV between SCM and pre-laryngeal-/ pre-tracheal muscles / thyroid gland is sometimes not visible. In that case a target is defined anyway, as a 3 mm wide line.

### Level V

**Clarification:** The posterior border of level 5 is defined as an arbitrary horizontal line from the antero-lateral border of the trapezoid muscle.

**Clarification:** Above the hyoid bone, the space between the posterior border of SCM and trapezoid muscle is called the occipital level (Xb) and should be included in patient with cranial posterior nodes, e.g. in nasopharyngeal cancer patients

### Level VIIb

**Clarification:** The upper border of the jugular foramen forms the cranial boundary

## Appendix 5 Nasopharynx CTV2 Atlas

See Dahanca.dk

## 8. About this clinical guideline

This clinical practice guideline is developed in collaboration between the Danish Multidisciplinary Cancer Groups (DMCG.dk) and the Danish Healthcare Quality Institute (SundK). The development is part of an intensified guideline effort launched in relation to the National Cancer Plan IV. The aim is to support high-quality cancer care across the Danish healthcare system. The guideline content is approved by the disease-specific Multidisciplinary Cancer Group, whereas the format is approved by the Center for Clinical Practice Guidelines | Cancer. Further information about clinical practice guidelines concerning cancer treatment in Denmark can be found here: [www.dmcg.dk/kliniske-retningslinjer](http://www.dmcg.dk/kliniske-retningslinjer)

The guideline targets clinically active healthcare professionals in the Danish healthcare system and contains systematically developed statements that can be used as decision support by professionals and patients when deciding on appropriate and correct healthcare services in specific clinical situations.

Clinical practice guidelines concerning Danish cancer care is characterized as professional advice. The guidelines are not legally binding and professional judgment in the specific clinical context will always determine what the appropriate and correct medical care is. Adherence to the guideline recommendations is no guarantee for a successful outcome. Sometimes care corresponding to a lower level of evidence will be preferred due to the individual patient's situation.

The guideline includes, in addition to the central recommendations (chapter 1 – quick guide), a description of the basis for the recommendations – including the underlying evidence (chapter 3), references (chapter 4), and applied methods (chapter 5).

Recommendations marked A are based on the strongest evidence, while recommendations marked D are based on the weakest evidence. For further information on strength of evidence see the "Oxford Centre for Evidence-Based Medicine Levels of Evidence and Grades of Recommendations",

<https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>

This guideline also includes information on the target population (chapter 2) and the method of development (chapter 5) is also included in the guideline. See the table of contents for page references.

The guideline template has been prepared based on international quality requirements for the development of clinical guidelines as described by AGREE II, GRADE, and RIGHT.

For information on the Danish Health Authority's cancer packages – descriptions of the entire standard patient pathway specifying requirements for timelines and content – refer to the relevant disease area at:

<https://www.sst.dk/en/english>

The Danish Health Authority (National Cancer Plan IV) and the Danish Healthcare Quality Institute (SundK) funded the development of this clinical practice guideline.